WO2023025319A1 - 一种新型的胞苷衍生物及其药物组合物和用途 - Google Patents
一种新型的胞苷衍生物及其药物组合物和用途 Download PDFInfo
- Publication number
- WO2023025319A1 WO2023025319A1 PCT/CN2022/115474 CN2022115474W WO2023025319A1 WO 2023025319 A1 WO2023025319 A1 WO 2023025319A1 CN 2022115474 W CN2022115474 W CN 2022115474W WO 2023025319 A1 WO2023025319 A1 WO 2023025319A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- virus
- formula
- group
- unsubstituted
- Prior art date
Links
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 title claims abstract description 33
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 275
- 230000009385 viral infection Effects 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims description 98
- 229910052739 hydrogen Inorganic materials 0.000 claims description 56
- 239000001257 hydrogen Substances 0.000 claims description 56
- 150000002431 hydrogen Chemical class 0.000 claims description 39
- 150000003839 salts Chemical class 0.000 claims description 39
- 241000700605 Viruses Species 0.000 claims description 35
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 33
- 125000003118 aryl group Chemical group 0.000 claims description 21
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 21
- 125000003545 alkoxy group Chemical group 0.000 claims description 20
- 229910052736 halogen Inorganic materials 0.000 claims description 19
- 150000002367 halogens Chemical group 0.000 claims description 19
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 18
- 125000001424 substituent group Chemical group 0.000 claims description 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 17
- -1 chlorophenylcarbonyl Chemical group 0.000 claims description 14
- 241000712461 unidentified influenza virus Species 0.000 claims description 14
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 13
- 241000711573 Coronaviridae Species 0.000 claims description 13
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 230000000155 isotopic effect Effects 0.000 claims description 8
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims description 7
- 125000001072 heteroaryl group Chemical group 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 241000315672 SARS coronavirus Species 0.000 claims description 6
- 125000004104 aryloxy group Chemical group 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 5
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims description 5
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 5
- 239000003443 antiviral agent Substances 0.000 claims description 5
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 5
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 229910052805 deuterium Inorganic materials 0.000 claims description 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 5
- 241000712892 Arenaviridae Species 0.000 claims description 4
- 241001678559 COVID-19 virus Species 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 241000709661 Enterovirus Species 0.000 claims description 4
- 241000711950 Filoviridae Species 0.000 claims description 4
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 4
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 4
- 241000701161 unidentified adenovirus Species 0.000 claims description 4
- 241000712902 Lassa mammarenavirus Species 0.000 claims description 3
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 2
- 241000712431 Influenza A virus Species 0.000 claims description 2
- 241000713196 Influenza B virus Species 0.000 claims description 2
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 claims 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
- 239000004576 sand Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 12
- 239000003814 drug Substances 0.000 abstract description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 96
- 238000006243 chemical reaction Methods 0.000 description 74
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 67
- 230000015572 biosynthetic process Effects 0.000 description 37
- 238000003786 synthesis reaction Methods 0.000 description 37
- 239000000243 solution Substances 0.000 description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 24
- 238000003756 stirring Methods 0.000 description 24
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- 239000000203 mixture Substances 0.000 description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- 239000007858 starting material Substances 0.000 description 18
- 229940126062 Compound A Drugs 0.000 description 17
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 17
- 239000012074 organic phase Substances 0.000 description 16
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 14
- 206010022000 influenza Diseases 0.000 description 14
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
- 239000010410 layer Substances 0.000 description 12
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000004440 column chromatography Methods 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- ZRWNRAJCPNLYAK-UHFFFAOYSA-N 4-bromobenzamide Chemical compound NC(=O)C1=CC=C(Br)C=C1 ZRWNRAJCPNLYAK-UHFFFAOYSA-N 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- 239000005457 ice water Substances 0.000 description 7
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 6
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- 150000001299 aldehydes Chemical class 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 239000005723 virus inoculator Substances 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 150000001241 acetals Chemical class 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 4
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- IKGLACJFEHSFNN-UHFFFAOYSA-N hydron;triethylazanium;trifluoride Chemical compound F.F.F.CCN(CC)CC IKGLACJFEHSFNN-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- JAPYIBBSTJFDAK-UHFFFAOYSA-N 2,4,6-tri(propan-2-yl)benzenesulfonyl chloride Chemical compound CC(C)C1=CC(C(C)C)=C(S(Cl)(=O)=O)C(C(C)C)=C1 JAPYIBBSTJFDAK-UHFFFAOYSA-N 0.000 description 2
- GGNMTJKRHHLJHH-UHFFFAOYSA-N 3,4,5-trimethoxybenzamide Chemical group COC1=CC(C(N)=O)=CC(OC)=C1OC GGNMTJKRHHLJHH-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 2
- 229940045803 cuprous chloride Drugs 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 1
- XURBWYCGQQXTHJ-UHFFFAOYSA-N 3,4-dichlorobenzamide Chemical group NC(=O)C1=CC=C(Cl)C(Cl)=C1 XURBWYCGQQXTHJ-UHFFFAOYSA-N 0.000 description 1
- XBGXGCOLWCMVOI-UHFFFAOYSA-N 3-(trifluoromethyl)benzamide Chemical group NC(=O)C1=CC=CC(C(F)(F)F)=C1 XBGXGCOLWCMVOI-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical class NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QIKYZXDTTPVVAC-UHFFFAOYSA-N 4-Aminobenzamide Chemical group NC(=O)C1=CC=C(N)C=C1 QIKYZXDTTPVVAC-UHFFFAOYSA-N 0.000 description 1
- QGHDLJAZIIFENW-UHFFFAOYSA-N 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxy-3-prop-2-enylphenyl)propan-2-yl]-2-prop-2-enylphenol Chemical group C1=C(CC=C)C(O)=CC=C1C(C(F)(F)F)(C(F)(F)F)C1=CC=C(O)C(CC=C)=C1 QGHDLJAZIIFENW-UHFFFAOYSA-N 0.000 description 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
- GUCPYIYFQVTFSI-UHFFFAOYSA-N 4-methoxybenzamide Chemical group COC1=CC=C(C(N)=O)C=C1 GUCPYIYFQVTFSI-UHFFFAOYSA-N 0.000 description 1
- ZESWUEBPRPGMTP-UHFFFAOYSA-N 4-nitrobenzamide Chemical compound NC(=O)C1=CC=C([N+]([O-])=O)C=C1 ZESWUEBPRPGMTP-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical class OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 231100000645 Reed–Muench method Toxicity 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- IHNHAHWGVLXCCI-FDYHWXHSSA-N [(2r,3r,4r,5s)-3,4,5-triacetyloxyoxolan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O IHNHAHWGVLXCCI-FDYHWXHSSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 229940124393 anti-influenza virus drug Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- PJBIHXWYDMFGCV-UHFFFAOYSA-N chloro(chlorosulfonyloxy)methane Chemical compound ClCOS(Cl)(=O)=O PJBIHXWYDMFGCV-UHFFFAOYSA-N 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- CHVJITGCYZJHLR-UHFFFAOYSA-N cyclohepta-1,3,5-triene Chemical class C1C=CC=CC=C1 CHVJITGCYZJHLR-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical class [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- QTBSBXVTEAMEQO-DYCDLGHISA-N deuterio acetate Chemical compound [2H]OC(C)=O QTBSBXVTEAMEQO-DYCDLGHISA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical class OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012527 feed solution Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical class OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- RCBVKBFIWMOMHF-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O RCBVKBFIWMOMHF-UHFFFAOYSA-L 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- MJTGQALMWUUPQM-UHFFFAOYSA-N m-Chlorobenzamide Chemical group NC(=O)C1=CC=CC(Cl)=C1 MJTGQALMWUUPQM-UHFFFAOYSA-N 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- HVZWVEKIQMJYIK-UHFFFAOYSA-N nitryl chloride Chemical compound [O-][N+](Cl)=O HVZWVEKIQMJYIK-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical class C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Definitions
- the present invention relates to but not limited to the technical field of medicinal chemistry, and in particular relates to a novel cytidine derivative and its pharmaceutical composition and use.
- Influenza is an acute respiratory infection caused by influenza virus infection. In China, millions of people report influenza-like patients every winter, and influenza is accompanied by high attack rate and mortality. It is a particularly important disease in high-risk groups such as infants and the elderly. Among the elderly, the complication rate of pneumonia is high, and the elderly account for the majority of deaths due to influenza.
- the present inventors have developed a novel cytidine derivative which has antiviral effects and low cytotoxicity.
- One aspect of the present invention provides a novel cytidine derivative, tautomer, stereoisomer, isotope derivative and pharmaceutically acceptable salt thereof as shown in (I 0 ):
- R 1 and R 2 are independently selected from hydrogen, Alternatively, R and R form an acetal or ketal with their adjacent oxygen;
- n 1 is selected from 0, 1, 2 or 3;
- n 2 is selected from 1, 2 or 3;
- R a and R b are independently selected from hydroxyl, the following groups substituted or unsubstituted by one or more groups A: C1-C8 alkyl, C1-C8 alkoxy, C2-C8 alkenyl, C3- C8 cycloalkyl, C6-C18 aryl, aryloxy, arylalkyl, alkylaryl;
- R c and R d are independently selected from hydrogen, C1-C8 alkyl groups substituted or unsubstituted by one or more groups A;
- R 3 and R 4 are the same or different, independently selected from hydrogen or R 3 and R 4 cannot both be hydrogen;
- na is selected from 0, 1, 2, 3, 4, or 5;
- n b is selected from 1, 2, 3, 4, or 5;
- n 3 is selected from 0, 1, 2, 3, 4, or 5;
- n 4 is selected from 0, 1, 2, 3, or 4;
- R 5 and R 6 are the same or different, independently selected from hydrogen, C1-C8 alkyl substituted or unsubstituted by one or more groups A; or the carbon to which R 5 and R 6 are connected forms a cycloalkyl group;
- R 7 is hydrogen, halogen, amino, C1-C8 alkyl substituted or unsubstituted by one or more groups A;
- n 5 are independently 0, 1, 2, 3, 4, or 5;
- R is selected from H, hydroxyl, nitro, halogen, the following groups substituted or unsubstituted by one or more groups A: amino, C1-C8 alkyl, C6-C18 aryl, C1-C8 alkoxy , aminoalkyl, C1-C8 alkylaryl, arylcarbonyl, C1-C8 alkylcarbonyloxy;
- R e and R f are independently selected from hydrogen, the following groups substituted or unsubstituted by one or more groups A: C1-C8 alkyl, C3-C8 cycloalkyl, heterocycloalkyl, C6-C18 Aryl, heteroaryl, non-aromatic heterocyclic;
- R X1 , R X2 , R X3 , R X4 , R X5 , R X6 , R X7 and R X8 are independently selected from hydrogen and deuterium;
- the group A is: hydroxyl, carboxyl, amino, halogen, cyano, aldehyde, nitro, trifluoromethyl, C3-C8 cycloalkyl, C1-C8 alkoxy, chlorophenylcarbonyl.
- the present invention provides a novel cytidine derivative, tautomer, stereoisomer, isotope derivative and pharmaceutically acceptable derivative thereof as shown in formula (I 0 -1) Salt:
- the present invention provides a novel cytidine derivative, tautomer, stereoisomer, isotope derivative and pharmaceutically acceptable Salt:
- the present invention provides a novel cytidine derivative, tautomer, stereoisomer, isotope derivative and pharmaceutically acceptable salt thereof such as formula (I 0 -3):
- the present invention provides a novel cytidine derivative, tautomer, stereoisomer, isotope derivative and pharmaceutically acceptable salt thereof such as formula (I 0 -4):
- One aspect of the present invention provides a novel cytidine derivative, tautomer, stereoisomer, and pharmaceutically acceptable salt thereof as shown in (I 0 -1):
- R 1 and R 2 are the same or different, each independently selected from hydrogen, Alternatively, R and R together form an acetal or ketal with their adjacent oxygen;
- n1 and n2 are selected from 0, 1, 2 or 3;
- R a and R b are independently selected from hydroxyl, alkyl substituted or unsubstituted by group A, alkoxy substituted or unsubstituted by group A, alkenyl substituted or unsubstituted by group A, Cycloalkyl substituted or unsubstituted by group A, aryl substituted or unsubstituted by group A, aryloxy substituted or unsubstituted by group A, arylalkyl substituted or unsubstituted by group A A group, an alkylaryl group substituted or unsubstituted by a group A;
- R c and R d are independently selected from hydrogen, C1-C8 alkyl substituted or unsubstituted by group A;
- R 3 and R 4 are the same or different, independently selected from hydrogen and R 3 and R 4 cannot both be hydrogen;
- n a , n b and n 3 are independently selected from 0, or 1, or 2, or 3, or 4, or 5;
- n4 is selected from 0, 1, 2, 3 or 4;
- R 5 and R 6 are the same or different, independently selected from hydrogen, C1-C8 alkyl substituted or unsubstituted by group A; or C cycloalkyl connected to R 5 and R 6 ;
- R 7 is selected from hydrogen, halogen, amino, substituted or unsubstituted C1-C8 alkyl by group A;
- n 5 are independently 0, or 1, or 2, or 3, or 4, or 5;
- R 8 is selected from H, hydroxyl, halogen, amino substituted or unsubstituted by group A, C1-C8 alkyl substituted or unsubstituted by group A, aryl substituted or unsubstituted by group A, substituted by group A C1-C8 alkyloxy group substituted or unsubstituted by group A, aminoalkyl group substituted or unsubstituted by group A, C1-C8 alkylaryl group substituted or unsubstituted by group A, substituted group Group A substituted or unsubstituted arylcarbonyl, group A substituted or unsubstituted C1-C8 alkylcarbonyloxy;
- the group A is: hydroxyl, carboxyl, amino, halogen, cyano, aldehyde, nitro, trifluoromethyl, C3-C8 cycloalkyl, C1-C8 alkoxy, chlorophenylcarbonyl.
- the present invention provides a novel cytidine derivative, tautomer, stereoisomer, isotope derivative and pharmaceutically acceptable derivative thereof such as formula (I 0 -1-1) Salt:
- the present invention provides a novel cytidine derivative, tautomer, stereoisomer, isotope derivative and pharmaceutically acceptable derivative thereof such as formula (I 0 -1-2) Salt:
- the present invention provides a novel cytidine derivative, tautomer, stereoisomer, isotope derivative and pharmaceutically acceptable derivative thereof such as formula (I 0 -1-3) Salt:
- One aspect of the present invention provides a novel cytidine derivative, tautomer, stereoisomer, and pharmaceutically acceptable salt thereof as shown in (I 0 -1):
- R 1 and R 2 are independently selected from hydrogen, Alternatively, R and R together form an acetal or ketal with their adjacent oxygen;
- n1 and n2 are selected from 0, 1, 2 or 3;
- R a and R b are independently selected from hydroxyl, alkyl substituted or unsubstituted by group A, alkoxy substituted or unsubstituted by group A, alkenyl substituted or unsubstituted by group A, Cycloalkyl substituted or unsubstituted by group A, aryl substituted or unsubstituted by group A, aryloxy substituted or unsubstituted by group A, arylalkyl substituted or unsubstituted by group A A group, an alkylaryl group substituted or unsubstituted by a group A;
- R c and R d are independently selected from hydrogen, C1-C8 alkyl substituted or unsubstituted by group A;
- R 3 and R 4 are the same or different, each independently selected from hydrogen, or R 3 and R 4 cannot be hydrogen at the same time;
- n a and n b are independently selected from 1, or 2, or 3, or 4, or 5;
- n 3 is selected from 0, or 1, or 2, or 3, or 4, or 5;
- n4 is selected from 0, 1, 2, 3 or 4;
- R 5 and R 6 are the same or different, independently selected from hydrogen, C1-C8 alkyl substituted or unsubstituted by group A; or the carbon to which R 5 and R 6 are connected forms a cycloalkyl group;
- R 7 is hydrogen, halogen, amino, C1-C8 alkyl substituted or unsubstituted by group A;
- n and 5 are independently 0, or 1, or 2, or 3, or 4, or 5;
- R 8 is selected from H, hydroxyl, halogen, amino substituted or unsubstituted by group A, C1-C8 alkyl substituted or unsubstituted by group A, aryl substituted or unsubstituted by group A, substituted by group A C1-C8 alkyloxy group substituted or unsubstituted by group A, aminoalkyl group substituted or unsubstituted by group A, C1-C8 alkylaryl group substituted or unsubstituted by group A, substituted group Group A substituted or unsubstituted arylcarbonyl, group A substituted or unsubstituted C1-C8 alkylcarbonyloxy;
- R e and R f are independently selected from hydrogen, the following groups substituted or unsubstituted by one or more groups A: C1-C8 alkyl, C3-C8 cycloalkyl, heterocycloalkyl, C6-C18 Aryl, heteroaryl, non-aromatic heterocyclic; wherein, R e and R f cannot be hydrogen at the same time;
- the group A is: hydroxyl, carboxyl, amino, halogen, cyano, aldehyde, nitro, trifluoromethyl, C3-C8 cycloalkyl, C1-C8 alkoxy, chlorophenylcarbonyl.
- the present invention provides a novel cytidine derivative, tautomer, stereoisomer, isotope derivative and pharmaceutically acceptable derivative thereof such as formula (I 0 -1-1) Salt:
- the present invention provides a novel cytidine derivative, tautomer, stereoisomer, isotope derivative and pharmaceutically acceptable derivative thereof such as formula (I 0 -1-2) Salt:
- the present invention provides a novel cytidine derivative, tautomer, stereoisomer, isotope derivative and pharmaceutically acceptable derivative thereof such as formula (I 0 -1-3) Salt:
- One aspect of the present invention provides a novel cytidine derivative, tautomer, stereoisomer, and pharmaceutically acceptable salt thereof as shown in (I 0 -5):
- R 1 and R 2 are independently selected from hydroxyl, In particular, when R x6 and R x7 are both hydrogen or deuterium, and R 1 and R 2 are independently selected from C1-8 alkoxy groups, R 1 and R 2 can form acetal or Ketal;
- n 1 and n 2 are independently selected from 0, 1, 2 or 3;
- R a and R b are independently selected from the following groups: hydroxyl, substituted or unsubstituted by one or more groups A: alkyl, alkoxy, alkenyl, cycloalkyl, aryl, aryloxy, Arylalkyl, alkylaryl;
- R c and R d are independently selected from hydrogen, C1-C8 alkyl groups substituted or unsubstituted by one or more groups A;
- R 3 and R 4 are the same or different, each independently selected from hydrogen, or R 3 and R 4 cannot be hydrogen at the same time;
- n a , n b and n 3 are independently selected from 0, or 1, or 2, or 3, or 4, or 5, respectively;
- n4 is selected from 0, 1, 2, 3 or 4;
- R 5 and R 6 are the same or different, independently selected from hydrogen, C1-C8 alkyl substituted or unsubstituted by one or more groups A; or the carbon to which R 5 and R 6 are connected forms a cycloalkyl group;
- R 7 is hydrogen, halogen, amino, C1-C8 alkyl substituted or unsubstituted by one or more groups A;
- n and 5 are independently 0, or 1, or 2, or 3, or 4, or 5;
- R 8 is selected from H, hydroxyl, halogen, the following groups substituted or unsubstituted by one or more groups A: amino, C1-C8 alkyl, aryl, alkyloxy, one or more groups Group A substituted or unsubstituted aminoalkyl, C1-C8 alkylaryl, arylcarbonyl, C1-C8 alkylcarbonyloxy;
- R e and R f are independently selected from hydrogen, the following groups substituted or unsubstituted by one or more groups A: C1-C8 alkyl, C3-C8 cycloalkyl, heterocycloalkyl, C6-C18 Aryl, heteroaryl, non-aromatic heterocyclic;
- R X1 , R X2 , R X3 , R X4 , R X5 , R X6 , R X7 and R X8 are each independently selected from hydrogen, deuterium, in particular, R X1 , R X2 , R X3 , R X4 , R X5 , R X6 , R X7 and R X8 cannot be hydrogen at the same time.
- the group A is: hydroxyl, carboxyl, amino, halogen, cyano, aldehyde, nitro, trifluoromethyl, C3-C8 cycloalkyl, C1-C8 alkoxy, chlorophenylcarbonyl.
- R X1 , R X2 , R X3 , and R X4 are independently selected from hydrogen and deuterium;
- R X1 , R X2 , R X3 , R X4 , R X5 , R X6 , R X7 and R X8 are all hydrogen.
- R X5 , R X6 , R X7 and R X8 are all hydrogen.
- both R 1 and R 2 are hydrogen;
- R 1 is hydrogen
- R 2 is selected from wherein n is selected from 0, 1 , 2 or 3;
- n is selected from 0 or 1;
- n 2 is selected from 1, 2 or 3;
- n 1 ;
- R a and R b are independently selected from hydroxyl, the following groups substituted or unsubstituted by one or more groups A: C1-C8 alkyl, C1-C8 alkoxy, aryloxy, alkylaryl base;
- R a and R b are each independently preferably selected from the following groups substituted or unsubstituted by hydroxyl, one or more groups A: C1-C8 alkyl, C1-C8 alkyl Oxygen;
- R 2 is hydrogen, and R 1 is selected from wherein, the above n 1 , n 2 , R a and R b are as defined above;
- neither R 1 nor R 2 is hydrogen, each independently selected from Wherein, the above n 1 , n 2 , R a and R b are respectively as defined above.
- R 4 is hydrogen
- R 3 is
- na is selected from 0, 1, 2, or 3;
- na is 0;
- na 1;
- n b is selected from 0, 1, 2, or 3;
- n b is 1;
- n is selected from 0, 1, 2, 3 ;
- n is 0 ;
- n 2 ;
- n 3 ;
- n is selected from 0, 1, 2;
- n4 is 0;
- n4 is 2;
- R e is hydrogen
- R f is the following groups substituted or unsubstituted by one or more groups A: C1-C8 alkyl, C3-C8 cycloalkyl, heterocycloalkyl, C6-C18 aryl, heteroaryl, non-aromatic heterocyclic group;
- R e is hydrogen, and R f is methyl
- R e and R f are C1-C8 alkyl groups substituted or unsubstituted by group A;
- R e and R f are both C1-C8 alkyl
- R 5 and R 6 are the same or different, independently selected from hydrogen, C1-C8 alkyl substituted or unsubstituted by one or more groups A; or R 5 and R 6 are connected to them C is a cycloalkyl group;
- R 5 and R 6 are both C1-C4 alkyl; preferably, R 5 and R 6 are both methyl groups;
- R 5 is methyl
- R 6 is selected from C1-C4 alkyl substituted or unsubstituted by one or more groups A; preferably, R 5 is methyl, R 6 is ethyl ;
- R 7 is hydrogen, halogen, amino, C1-C8 alkyl substituted or unsubstituted by one or more groups A;
- R 7 is selected from hydrogen, or methyl
- Z above is
- n 5 is selected from 0, 1, 2, 3, 4, or 5;
- n 5 is preferably selected from 0, 1, or 2;
- the above-mentioned R 8 is selected from hydrogen, hydroxyl, nitro, halogen, the following groups substituted or unsubstituted by one or more groups A: amino, C1-C8 alkyl, C6-C18 aromatic group, C1-C8 alkoxy group, C1-C8 alkylaryl group, C1-C8 alkylcarbonyloxy group;
- R 8 is preferably selected from hydrogen, nitro, chlorine, bromine, the following groups substituted or unsubstituted by one or more groups A: amino, C1-C3 alkyl, C6 -C18 aryl, C1-C3 alkoxy, C1-C3 alkylcarbonyloxy;
- the above-mentioned Z is selected from 4-chlorophenylcarbonyl, hydrogen, chlorine, 4-chlorobenzyl,
- the group A is: hydroxyl, carboxyl, amino, halogen, cyano, aldehyde, nitro, trifluoromethyl, C3-C8 cycloalkyl, C1-C8 alkoxy, chlorophenylcarbonyl.
- R 3 and R 4 are both Wherein, Z, R 5 , R 6 , R 7 , Re , R f , na , n b , n 3 and n 4 are as defined above.
- R 3 is hydrogen
- R 4 is Wherein, Z, R 5 , R 6 , R 7 , Re , R f , na , n b , n 3 and n 4 are as defined above.
- the above-mentioned novel cytidine derivatives, tautomers, stereoisomers, isotopic derivatives and pharmaceutically acceptable salts thereof provided by the present invention are selected from the following compounds:
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising the above-mentioned novel cytidine derivatives, tautomers, stereoisomers, isotopic derivatives and pharmaceutically acceptable salts thereof.
- the present invention discloses a pharmaceutical composition, which uses the compound, isomer or pharmaceutically acceptable salt thereof as the active ingredient or the main active ingredient, supplemented by pharmaceutically acceptable carrier composition.
- the present invention provides the above-mentioned novel cytidine derivatives, tautomers, stereoisomers, isotopic derivatives and pharmaceutically acceptable salts thereof, which can be used for the treatment and/or prevention of Diseases associated with antiviral conditions.
- the present invention provides the application of the above-mentioned pharmaceutical composition in the preparation of antiviral drugs; wherein, the above-mentioned viruses include, but are not limited to: Arenaviridae, Filoviridae and Coronaviridae viruses, etc. , including but not limited to adenovirus, rhinovirus, influenza virus, Lassa virus, respiratory syncytial virus, severe acute respiratory syndrome virus, parainfluenza virus, coronavirus, etc.
- the present invention provides the application of the above-mentioned pharmaceutical composition in the preparation of antiviral drugs; wherein, the above-mentioned influenza virus and coronavirus include but are not limited to: influenza A virus, influenza B virus, SARS virus, MERS virus, COVID-19 virus, etc.
- the present invention provides a method for treating or preventing viral infection in an individual, comprising administering a therapeutically effective amount of the novel cytidine derivatives, tautomorphic compounds disclosed herein to an individual in need thereof.
- the virus infection includes but not limited to the infection of the following viruses: Arenaviridae, Filoviridae and coronaviruses, including but not limited to adenovirus, rhinovirus, influenza virus, Lassa virus, respiratory syncytial virus, severe acute respiratory syndrome virus, parainfluenza virus, coronavirus, etc.
- novel cytidine derivatives of the present invention can be formulated as pharmaceutical compositions, and administered to patients according to a variety of suitable administration methods, including systemic, such as oral or parenteral, intravenous , muscle, transdermal or subcutaneous, etc.
- the compound disclosed in the present invention has better stability.
- the compound disclosed by the present invention has better anti-influenza virus activity, lower cytotoxicity and higher selection index.
- the compound disclosed in the present invention has better anti-new coronavirus activity.
- the bioavailability of the compound disclosed in the present invention is nearly 1.4 times that of compound A, and has a better safety margin.
- the compound disclosed in the present invention Compared with the combination of compound A and compound C, the compound disclosed in the present invention has more excellent therapeutic effect and preventive effect in anti-influenza virus. According to the excellent therapeutic effect and preventive effect analysis, the compound of the present invention enters the body. , the two metabolic components played a certain synergistic effect.
- the compounds described in the present invention can be used as antiviral drugs with novel structures.
- Compound A has the following structure:
- Certain compounds of the present invention can exist in unsolvated or solvated forms, such as hydrates, ethanolates.
- the solvated forms are equivalent to unsolvated forms and are within the scope of the present invention.
- pharmaceutically acceptable refers to those compounds, materials, compositions and/or dosage forms which, within the scope of sound medical judgment, are suitable for use in contact with human and animal tissues without excessive Toxicity, irritation, allergic reaction, or other problems or complications, commensurate with a reasonable benefit/risk ratio.
- pharmaceutically acceptable salt refers to a salt of a compound of the present invention, which is prepared from a compound having a specific substituent found in the present invention and a relatively non-toxic acid or base.
- base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of base, either neat solution or in a suitable inert solvent.
- Pharmaceutically acceptable base addition salts include aluminum, sodium, potassium, calcium, manganese, iron, ammonium, organic ammonia or magnesium salts or similar salts.
- acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the acid, either neat solution or in a suitable inert solvent.
- pharmaceutically acceptable acid addition salts include salts of inorganic acids including, for example, hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, bicarbonate, phosphoric acid, monohydrogenphosphate, dihydrogenphosphate, sulfuric acid, Hydrogen sulfate, hydriodic acid, phosphorous acid, etc.; and organic acid salts, such as acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, Fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, tartaric acid and methanesulfonic acid and similar acids; also salts of inorganic acids including, for example,
- alkyl means a saturated aliphatic group, including straight and branched chain groups.
- the alkyl group may be substituted or unsubstituted.
- the substituent is preferably one or more, more preferably 1-3, most preferably 1 or 2 substituents.
- alkenyl means an aliphatic group containing an unsaturated carbon-carbon double bond, including straight chain and branched chain groups.
- the alkyl group may be substituted or unsubstituted. There can be one or more carbon-carbon double bonds.
- cycloalkyl means an all carbon monocyclic or fused ring ("fused" ring means that each ring in the system shares adjacent pairs of carbon atoms with other rings in the system) group, wherein One or more rings do not have a fully attached pi-electron system
- examples of cycloalkyl groups are cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, adamantane, cyclohexanedi alkenes, cycloheptanes, and cycloheptatrienes.
- Cycloalkyl groups can be substituted and unsubstituted.
- aryl denotes an all-carbon monocyclic or fused polycyclic group of 1 to 12 carbon atoms, having a fully conjugated pi-electron system.
- Non-limiting examples of aryl groups are phenyl, naphthyl and anthracenyl.
- Aryl groups can be substituted or unsubstituted. When substituted, the substituents are preferably one or more, more preferably one, two or three, still more preferably one or two.
- arylhydrocarbyl means a hydrocarbyl group substituted with an aryl group.
- heteroaryl means a multiatom monocyclic or fused ring group containing one, two, three or four ring heteroatoms selected from N, O or S, the remaining ring atoms being C, and It has a fully conjugated ⁇ -electron system.
- unsubstituted heteroaryl groups are pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyrimidine, quinoline, isoquinoline, purine, tetrazole, triazine and carbazole.
- alkoxy refers to a group in which an alkyl group is attached to an oxygen, where the alkyl group may be straight chain, branched or cyclic.
- hydroxyl means the -OH group.
- amino denotes a -NH2 group.
- halogen means fluorine, chlorine, bromine or iodine.
- pharmaceutically acceptable carrier refers to any preparation or carrier medium capable of delivering an effective amount of the active substance of the present invention, does not interfere with the biological activity of the active substance, and has no toxic side effects on the host or patient.
- Representative carriers include water, oil, Vegetables and minerals, cream bases, lotion bases, ointment bases, etc. These bases include suspending agents, viscosity builders, skin penetration enhancers and the like.
- stereoisomer refers to compounds that have identical chemical constitution, but differ in the arrangement of the atoms or groups in space.
- C1-C8 mean that the group can contain 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 8 carbon atoms.
- FIG. 1 shows is anti-influenza virus (H1N1) therapeutic administration test result.
- FIG. 2 shows the results of the prophylactic administration test against influenza virus (H1N1).
- Embodiment 1 the synthesis of compound PY-01
- Embodiment 2 the synthesis of compound PY-02
- step 1 of Example 1 compound PY-0101 was used to replace compound PY-01-SM1 to prepare compound PY-0201 (13.21 g), with a yield of 73.5%.
- ESI-MS (+): m/z 900.22.
- Embodiment 3 the synthesis of compound PY-03
- step 1 of Example 1 compound PY-0302 was used to replace compound PY-01-SM1 to prepare compound PY-0301 (18.6 g), with a yield of 76.2%.
- ESI-MS (+): m/z 902.40.
- Embodiment 4 the synthesis of compound ZJT1
- Embodiment 5 the synthesis of compound ZJT2
- Embodiment 6 the synthesis of compound ZJT3
- Embodiment 7 the synthesis of compound ZJT4
- Embodiment 8 the synthesis of compound ZJT5
- Embodiment 9 the synthesis of compound ZJT6
- Embodiment 10 the synthesis of compound ZJT7
- Embodiment 11 the synthesis of compound PY-ZJT8
- Embodiment 12 the synthesis of compound PY-ZJT9
- Embodiment 13 the synthesis of compound PY-04
- Embodiment 14 the synthesis of compound PY-05
- Embodiment 15 the synthesis of compound PY-06
- Embodiment 16 the synthesis of compound PY-07
- Embodiment 17 the synthesis of compound PY-08
- Embodiment 18 the synthesis of compound PY-09
- Embodiment 19 Synthesis of Compound PY-10
- Embodiment 20 the synthesis of compound PY-11
- step 1 Referring to the operation procedure of step 1 and step 2 in Example 1, compound PY-01-SM2 was replaced with compound ZJT7 to prepare compound PY-1102;
- compound ZJT12-01 (5.4g, 15.2mmol) was added to ethanol-D1 (200mL) at room temperature, and sodium borodeuteride-D4 (2.5g, 60.8mmol) was added all at once under stirring. After the addition was complete, it was stirred at room temperature for 1 hour, heated to 55°C for 7 hours, and then stirred at room temperature overnight. The system was cooled to 0°C, quenched with acetic acid-D1, evaporated to dryness under reduced pressure, and the residue was obtained by column chromatography to obtain compound ZJT12 (3.0 g), with a yield of 68.2%.
- ESI-MS(+):m/z 287.15
- Step 3-Step 5 Synthesis of Compound PY-56
- Embodiment 38 stability test
- Example 39 In vitro anti-influenza virus activity and cytotoxicity assay
- MDCK cells in the logarithmic growth phase were inoculated on 24-well cell culture plates, cultured in an incubator with 5% CO2 at 37°C for 24 hours, and then treated with drugs of different dilution concentrations for 2 hours, and then washed the plates with Hanks solution for 3 times. After drying, add 1ml DMEM maintenance solution containing 2% newborn calf serum to each well to maintain growth, and culture in an incubator at 37°C and 5% CO 2 .
- the cytopathic degree (CPE) was observed within 7 days, and the half-toxic concentration (TC 50 ) of the samples to the cells was calculated by Reed-Muench method.
- the MDCK cells in the logarithmic growth phase were inoculated in a 24-well plate containing about 1 ⁇ 10 4 cells per well, and cultured in a 5% CO 2 incubator at 37° C. After 24 hours, first infect the cells with virus solution (H1N1, A/WSN/33), wash twice with Hanks solution, then act on the cells with drug diluent, wash three times with Hanks solution, and finally wash with 2% newborn bovine serum The DMEM maintenance solution was incubated at 37 °C in a 5% CO 2 incubator.
- virus solution H1N1, A/WSN/33
- wash twice with Hanks solution then act on the cells with drug diluent
- wash three times with Hanks solution wash with 2% newborn bovine serum
- the DMEM maintenance solution was incubated at 37 °C in a 5% CO 2 incubator.
- CPE degree of cytopathic changes
- IC 50 half-inhibitory concentration
- the experimental results show that compared with the disclosed compound A, the detected compound sample of the present invention has better inhibitory activity on influenza virus (H1N1), lower cytotoxicity and higher selection index.
- Example 40 Determination of anti-new coronavirus activity (EC 50 ) in vitro
- Vero E6 cells were seeded into microwell plates at a certain density and cultured overnight in a 5% CO 2 , 37°C incubator. On the next day, compound (8 concentration points, triplicate wells) and SARS-CoV-2 virus (B.1.1.7(Alpha)) were added in serial dilution. Set up cell control (cells, no compound treatment or virus infection), virus control (cells infected with virus, no compound treatment). Cells were grown in an incubator for 3 or 4 days.
- the antiviral activity of the compound is represented by the inhibitory rate (%) of the compound at different concentrations on the cytopathic effect caused by the virus.
- GraphPad Prism was used to perform nonlinear fitting analysis on the inhibition rate of the compound, and the EC 50 of the compound was calculated. The results are shown in Table 3.
- Example 41 Evaluation of the pharmacokinetic characteristics of compound PY-01 in rats
- the two test products (PY-01 and compound A) were administered by single equimolar oral gavage and equimolar tail vein injection respectively. Fasting for 16-17 hours was started at 5:00 p.m. on the day before the administration, and the animals were given food 4 hours after the administration, and water could not be restrained during the whole process.
- Compound B has the following structure:
- Example 42 In vivo anti-influenza virus therapeutic administration test
- group 1 (vehicle group) was given 0.5% sodium carboxymethyl cellulose solution by intragastric administration
- group 2 was given control drug by intragastric administration (equimolar, compound A of 17.33mg/kg and compound C of 19.01mg/kg, combined medication)
- group 3-group 5 were given test drugs (PY-01 of 29.46mg/kg, PY-01 of 29.46mg/kg) PY-03, 29.46 mg/kg of PY-49);
- Group 6 began to administer 29.46 mg/kg of PY-01 48 hours after nasal inoculation of the virus.
- each group is equimolar administration, twice a day, group 1-group 5 administration or vehicle for 4 days, and group 6 administration for 3 days. Animals were sacrificed on the 5th day after virus inoculation, and lung tissue samples were collected, and the virus titer was determined after homogenization. The result is shown in Figure 1.
- Example 43 In vivo anti-influenza virus (H1N1) prophylactic administration test
- mice 6-8 weeks old, SPF level, female, were randomly divided into 6 groups, numbered as group 1, group 2, group 3, group 4, group 5 and group 6, 5 mice in each group .
- Each group started administration on day -1.
- 100 PFU of influenza virus H1N1, A/Puerto Rico/8/1934 was inoculated nasally, and the virus was inoculated 2 hours after the administration of the virus on the day of inoculation.
- group 1 (vehicle group) was administered with 0.5% sodium carboxymethylcellulose solution by intragastric administration; group 2 was administered with control drugs (Compound A of 17.33 mg/kg and Compound C of 19.01 mg/kg, in combination); Group 3-Group 5 were given different doses of the test drug by intragastric administration (PY-01 high, medium and low dose groups: 88.37mg/kg, 29.46mg/kg, 9.82mg/kg); Group 6 was given the test drug by intragastric administration High dose of PY-01 (88.37 mg/kg). All groups were administered in equimolar doses once a day, groups 1-5 were administered or vehicle for 5 days, and group 6 was administered for 2 days. Animals were sacrificed on the 4th day after virus inoculation, and lung tissue samples were collected, and the virus titer was determined after homogenization. The result is shown in Figure 2.
- each experimental group showed lower virus titers; when the same number of days of administration, compared with the joint administration group, the virus titers of the PY-01 high-dose group and middle-dose group lower degree; compared with group 3 (high dose of PY-01 administered 2 days before virus inoculation, 3 days after virus inoculation), group 6 (high dose of PY-01 administered 2 days before virus inoculation)
- group 3 high dose of PY-01 administered 2 days before virus inoculation, 3 days after virus inoculation
- group 6 high dose of PY-01 administered 2 days before virus inoculation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种新型的胞苷衍生物及其药物组合物和用途,所述胞苷衍生物如式(I 0)所示;该化合物可用于制备抗病毒感染的药物。
Description
本发明涉及但不限于药物化学技术领域,尤其涉及一种新型的胞苷衍生物及其药物组合物和用途。
流感是由于流感病毒的感染而引起的急性呼吸道感染病。在国内,每年冬季有数百万人的类流感患者的报告,流感伴随有高的罹患率和死亡率。在婴幼儿、老年人等高风险人群中是特别重要的疾病,老年人中,肺炎并发率高,老年人占了因流感而死亡的人数的大多数。
由于流感病毒具有高度变异性,出于对耐药株的岀现或副作用的问题、以及病原性或致死性的新型流感病毒的世界性大流行等的担心,抗流感病毒药物的开发任重道远,因此,本领域仍渴望开发新型结构的抗病毒药物。
发明内容
本发明人开发了一种新型的胞苷衍生物,该化合物具有抗病毒作用以及低的细胞毒性。
本发明一方面提供一种如(I
0)所示的新型的胞苷衍生物、互变异构体、立体异构体、同位素衍生物及其药学上可接受的盐:
式(I
0)中,
其中,n
1选自0、1、2或3;
n
2选自1、2或3;
R
a和R
b分别独立地选自羟基、被一个或多个基团A取代或未取代的下列基团:C1-C8烷基、C1-C8烷氧基、C2-C8烯基、C3-C8环烷基、C6-C18芳基、芳基氧基、芳基烷基、烷基芳基;
R
c和R
d分别独立地选自氢、被一个或多个基团A取代或未取代的C1-C8的烷基;
其中,n
a选自0、1、2、3、4、或5;
n
b选自1、2、3、4、或5;
n
3选自0、1、2、3、4、或5;
n
4选自0、1、2、3、或4;
R
5和R
6相同或不同,独立的选自氢、被一个或多个基团A取代或未取代的C1-C8烷基;或者R
5、R
6与其相连的碳成环烷基;
R
7为氢、卤素、氨基、被一个或多个基团A取代或未取代的C1-C8烷基;
其中,n
5分别独立的为0、1、2、3、4、或5;
R
8选自H、羟基、硝基、卤素、被一个或多个基团A取代或未取代的下列基团:氨基、C1-C8烷基、C6-C18芳基、C1-C8烷氧基、氨基烷基、C1-C8烷基芳基、芳基羰基、C1-C8的烷基羰基氧基;
R
e和R
f分别独立地选自氢、被一个或多个基团A取代或未取代的下列基团:C1-C8烷基、C3-C8环烷基、杂环烷基、C6-C18芳基、杂芳基、非芳香族杂环基;
R
X1、R
X2、R
X3、R
X4、R
X5、R
X6、R
X7和R
X8分别独立地选自氢、氘;
所述基团A为:羟基、羧基、氨基、卤素、氰基、醛基、硝基、三氟甲基、C3-C8的环烷基、C1-C8的烷氧基、氯苯羰基。
在一些实施方案中,本发明提供一种如式(I
0-1)所示的新型的胞苷衍生物、互变异构体、立体异构体、同位素衍生物及其药学上可接受的盐:
式(I
0-1)中取代基的定义如前所述。
在一些实施方案中,本发明提供一种如式(I
0-2)所示的新型的胞苷衍生物、互变异构体、立体异构体、同位素衍生物及其药学上可接受的盐:
式(I
0-2)中取代基的定义如前所述。
在一些实施方案中,本发明提供一种如式(I
0-3)的新型的胞苷衍生物、 互变异构体、立体异构体、同位素衍生物及其药学上可接受的盐:
式(I
0-3)中取代基的定义如前所述。在一些实施方案中,本发明提供一种如式(I
0-4)的新型的胞苷衍生物、互变异构体、立体异构体、同位素衍生物及其药学上可接受的盐:
式(I
0-4)中取代基的定义如前所述。
本发明一方面提供一种如(I
0-1)所示的新型的胞苷衍生物、互变异构体、立体异构体、及其药学上可接受的盐:
式(I
0-1)中,
其中,n
1和n
2选自0、1、2或3;
R
a和R
b分别独立地选自羟基、被基团A取代或未取代的烷基、被基团A取代或未取代的烷氧基、被基团A取代或未取代的烯基、被基团A取代或未取代的环烷基、被基团A取代或未取代的芳基、被基团A取代或未取代的芳基氧基、被基团A取代或未取代的芳基烷基、被基团A取代或未取代的烷基芳基;
R
c和R
d分别独立地选自氢、被基团A取代或未取代的C1-C8的烷基;
其中,n
a、n
b和n
3分别独立地选自0、或1、或2、或3、或4、或5;
n
4选自0、1、2、3或4;
R
5和R
6相同或不同,独立的选自氢、被基团A取代或未取代的C1-C8烷基;或者R
5、R
6与其相连的C成环烷基;
R
7选自氢、卤素、氨基、被基团A取代或未取代的C1-C8烷基;
其中,n
5分别独立的为0、或1、或2、或3、或4、或5;
R
8选自H、羟基、卤素、被基团A取代或未取代的氨基、被基团A取代或未取代的C1-C8的烷基、被基团A取代或未取代的芳基、被基团A取代或未取代的C1-C8的烷基氧基、被基团A取代或未取代的氨基烷基、被基团A取代或未取代的C1-C8的烷基芳基、被基团A取代或未取代的芳基羰基、被基团A取代或未取代的C1-C8的烷基羰基氧基;
所述基团A为:羟基、羧基、氨基、卤素、氰基、醛基、硝基、三氟甲基、C3-C8的环烷基、C1-C8的烷氧基、氯苯羰基。
在一些实施方案中,本发明提供一种如式(I
0-1-1)的新型的胞苷衍生物、互变异构体、立体异构体、同位素衍生物及其药学上可接受的盐:
式(I
0-1-1)中取代基的定义如前所述。
在一些实施方案中,本发明提供一种如式(I
0-1-2)的新型的胞苷衍生物、互变异构体、立体异构体、同位素衍生物及其药学上可接受的盐:
式(I
0-1-2)中取代基的定义如前所述。
在一些实施方案中,本发明提供一种如式(I
0-1-3)的新型的胞苷衍生物、互变异构体、立体异构体、同位素衍生物及其药学上可接受的盐:
式(I
0-1-3)中取代基的定义如前所述。
本发明一方面提供一种如(I
0-1)所示的新型的胞苷衍生物、互变异构体、立体异构体、及其药学上可接受的盐:
式(I
0-1)中,
其中,n
1和n
2选自0、1、2或3;
R
a和R
b分别独立地选自羟基、被基团A取代或未取代的烷基、被基团A取代或未取代的烷氧基、被基团A取代或未取代的烯基、被基团A取代或未取代的环烷基、被基团A取代或未取代的芳基、被基团A取代或未取代的芳基氧基、被基团A取代或未取代的芳基烷基、被基团A取代或未取代的烷基芳基;
R
c和R
d分别独立地选自氢、被基团A取代或未取代的C1-C8的烷基;
其中,n
a和n
b分别独立地选自1、或2、或3、或4、或5;
n
3选自0、或1、或2、或3、或4、或5;
n
4选自0、1、2、3或4;
R
5和R
6相同或不同,独立的选自氢、被基团A取代或未取代的C1-C8 烷基;或者R
5、R
6与其相连的碳成环烷基;
R
7为氢、卤素、氨基、被基团A取代或未取代的C1-C8烷基;
n
5分别独立的为0、或1、或2、或3、或4、或5;
R
8选自H、羟基、卤素、被基团A取代或未取代的氨基、被基团A取代或未取代的C1-C8的烷基、被基团A取代或未取代的芳基、被基团A取代或未取代的C1-C8的烷基氧基、被基团A取代或未取代的氨基烷基、被基团A取代或未取代的C1-C8的烷基芳基、被基团A取代或未取代的芳基羰基、被基团A取代或未取代的C1-C8的烷基羰基氧基;
R
e和R
f分别独立地选自氢、被一个或多个基团A取代或未取代的下列基团:C1-C8烷基、C3-C8环烷基、杂环烷基、C6-C18芳基、杂芳基、非芳香族杂环基;其中,R
e和R
f不能同时为氢;
所述基团A为:羟基、羧基、氨基、卤素、氰基、醛基、硝基、三氟甲基、C3-C8的环烷基、C1-C8的烷氧基、氯苯羰基。
在一些实施方案中,本发明提供一种如式(I
0-1-1)的新型的胞苷衍生物、互变异构体、立体异构体、同位素衍生物及其药学上可接受的盐:
式(I
0-1-1)中取代基的定义如前所述。
在一些实施方案中,本发明提供一种如式(I
0-1-2)的新型的胞苷衍生物、互变异构体、立体异构体、同位素衍生物及其药学上可接受的盐:
式(I
0-1-2)中取代基的定义如前所述。
在一些实施方案中,本发明提供一种如式(I
0-1-3)的新型的胞苷衍生物、互变异构体、立体异构体、同位素衍生物及其药学上可接受的盐:
式(I
0-1-3)中取代基的定义如前所述。
本发明一方面提供一种如(I
0-5)所示的新型的胞苷衍生物、互变异构体、立体异构体、及其药学上可接受的盐:
式(I
0-5)中,
其中,上述n
1和n
2分别独立地选自0、1、2或3;
R
a和R
b分别独立地选自羟基、被一个或多个基团A取代或未取代下列基团:烷基、烷氧基、烯基、环烷基、芳基、芳基氧基、芳基烷基、烷基芳基;
R
c和R
d分别独立地选自氢、被一个或多个基团A取代或未取代的C1-C8的烷基;
其中,n
a、n
b和n
3分别独立地选自0、或1、或2、或3、或4、或 5,;
n
4选自0、1、2、3或4;
R
5和R
6相同或不同,独立的选自氢、被一个或多个基团A取代或未取代的C1-C8烷基;或者R
5、R
6与其相连的碳成环烷基;
R
7为氢、卤素、氨基、被一个或多个基团A取代或未取代的C1-C8烷基;
n
5分别独立的为0、或1、或2、或3、或4、或5;
R
8选自H、羟基、卤素、被一个或多个基团A取代或未取代的下列基团:氨基、C1-C8的烷基、芳基、烷基氧基、被一个或多个基团A取代或未取代的氨基烷基、C1-C8的烷基芳基、芳基羰基、C1-C8的烷基羰基氧基;
R
e和R
f分别独立地选自氢、被一个或多个基团A取代或未取代的下列基团:C1-C8烷基、C3-C8环烷基、杂环烷基、C6-C18芳基、杂芳基、非芳香族杂环基;
R
X1、R
X2、R
X3、R
X4、R
X5、R
X6、R
X7和R
X8分别独立地选自氢、氘,特别地,R
X1、R
X2、R
X3、R
X4、R
X5、R
X6、R
X7和R
X8不能同时为氢。
所述基团A为:羟基、羧基、氨基、卤素、氰基、醛基、硝基、三氟甲基、C3-C8的环烷基、C1-C8的烷氧基、氯苯羰基。
在一些实施方案中,上述式(I
0)和/或(I
0-2)-(I
0-4)中,R
X1、R
X2、R
X3、R
X4分别独立地选自氢、氘;
在一些实施方案中,上述式(I
0-1)中,R
X1、R
X2、R
X3、R
X4、R
X5、R
X6、R
X7和R
X8均为氢。
在一些实施方案中,上述式(I
0-2)-(I
0-4)中,R
X5、R
X6、R
X7和R
X8均为氢。
在一些实施方案中,上述式(I
0)-(I
0-4)中,R
1和R
2均为氢;
在一些更具体地实施方案中,n
1选自0或1;
n
2选自1、2或3;
在一些更具体地实施方案中,n
2为1;
R
a和R
b分别独立地选自羟基、被一个或多个基团A取代或未取代的下列基团:C1-C8烷基、C1-C8烷氧基、芳基氧基、烷基芳基;
在一些更具体地实施方案中,上述R
a和R
b分别独立地优选自羟基、被一个或多个基团A取代或未取代的下列基团:C1-C8烷基、C1-C8烷基氧基;
在一些实施方案中,n
a选自0、1、2、或3;
在一些更具体地实施方案中,n
a为0;
在一些更具体地实施方案中,n
a为1;
在一些实施方案中,n
b选自0、1、2、或3;
在一些更具体地实施方案中,n
b为1;
在一些实施方案中,n
3选自0、1、2、3;
在一些更具体地实施方案中,n
3为0;
在一些更具体地实施方案中,n
3为2;
在一些更具体地实施方案中,n
3为3;
在一些实施方案中,n
4选自0、1、2;
在一些更具体地实施方案中,n
4为0;
在一些更具体地实施方案中,n
4为2;
在一些实施方案中,上述R
e为氢,R
f为被一个或多个基团A取代或未取代的下列基团:C1-C8烷基、C3-C8环烷基、杂环烷基、C6-C18芳基、杂芳基、非芳香族杂环基;
在一些更具体地实施方案中,上述R
e为氢,R
f为甲基;
在一些实施方案中,上述R
e和R
f均为被基团A取代或未取代的C1-C8烷基;
在一些更具体地实施方案中,上述R
e和R
f均为C1-C8烷基;
在一些实施方案中,上述R
5和R
6相同或不同,独立的选自氢、被一个或多个基团A取代或未取代的C1-C8烷基;或者R
5、R
6与其相连的C成环烷基;
在一些更具体地实施方案中,上述R
5和R
6均为C1-C4烷基;优选地,R
5和R
6均甲基;
在一些实施方案中,上述R
5为甲基,R
6选自被一个或多个基团A取代或未取代的C1-C4烷基;优选地,R
5为甲基,R
6为乙基;
在一些实施方案中,上述R
7为氢、卤素、氨基、被一个或多个基团A 取代或未取代的C1-C8烷基;
在一些更具体地实施方案中,上述R
7选自氢、或甲基;
在一些实施方案中,上述n
5选自0、1、2、3、4、或5;
在一些更具体地实施方案中,上述n
5优选自0、1、或2;
在一些实施方案中,上述R
8选自氢、羟基、硝基、卤素、被一个或多个基团A取代或未取代的下列基团:氨基、C1-C8的烷基、C6-C18芳基、C1-C8的烷氧基、C1-C8的烷基芳基、C1-C8的烷基羰基氧基;
在一些更具体地实施方案中,上述R
8优选自氢、硝基、氯、溴、被一个或多个基团A取代或未取代的下列基团:氨基、C1-C3的烷基、C6-C18芳基、C1-C3的烷氧基、C1-C3的烷基羰基氧基;
所述基团A为:羟基、羧基、氨基、卤素、氰基、醛基、硝基、三氟甲基、C3-C8的环烷基、C1-C8的烷氧基、氯苯羰基。
在一些实施方案中,本发明提供的上述新型的胞苷衍生物、互变异构体、立体异构体、同位素衍生物及其药学上可接受的盐,选自下列化合物:
另一方面,在一些实施方案中,本发明提供了包含上述新型胞苷衍生物、互变异构体、立体异构体、同位素衍生物及其药学上可接受的盐的药物组合物。
在一些实施方案中,本发明公开了一种药物组合物,其以本发明所述的化合物、异构体或其药学上可接受的盐为活性成分或主要活性成分,辅以药学上可接受的载体组成。
再一方面,在一些实施方案中,本发明提供了上述新型胞苷衍生物、互变异构体、立体异构体、同位素衍生物及其药学上可接受的盐可用于治疗和/或预防与抗病毒相关病症的疾病。
在一些实施方案中,本发明提供了上述药物组合物可用于在制备抗病毒药物中的应用;其中,上述病毒,包括但不限于:沙粒病毒科、丝状病毒科和冠状病毒科病毒等,包括但不限于腺病毒、鼻病毒、流感病毒、拉沙病毒、呼吸道合胞病毒、严重急性呼吸综合症病毒、副流感病毒、冠状病毒等。
在一些实施方案中,本发明提供了上述药物组合物可用于在制备抗病毒药物中的应用;其中,上述的流感病毒和冠状病毒包括但不限于:甲型流感病毒、乙型流感病毒、SARS病毒、MERS病毒、COVID-19病毒等。
再一方面,在一些实施方案中,本发明提供了一种治疗或预防个体病毒感染的方法,包括对有相应需要的个体施用治疗有效量的本发明公开的新型胞苷衍生物、互变异构体、立体异构体、同位素衍生物及其药学上可接受的盐或上述的药物组合物;所述的病毒感染,包括但不限于如下病毒的感染:沙粒病毒科、丝状病毒科和冠状病毒科病毒等,包括但不限于腺病毒、鼻病毒、流感病毒、拉沙病毒、呼吸道合胞病毒、严重急性呼吸综合症病毒、副流感病毒、冠状病毒等。
在一些实施方案中,本发明所述新型胞苷衍生物可以被配制为药用组合物,按照多种合适选择的给予方式给患者用药,这些途径包括全身例如口服或胃肠外,通过静脉内、肌肉、透皮或皮下等。
本发明公开的化合物与CN111372592A公开的化合物A相比较,具有更好的稳定性。
本发明公开的化合物与CN111372592A公开的化合物A相比较,具有更好的抗流感病毒活性,更低的细胞毒性以及更高的选择指数。
本发明公开的化合物与化合物A相比较,具有更好的抗新冠病毒活性。
本发明公开的化合物生物利用度是化合物A的近1.4倍,且具有更好的安全范围。
本发明公开的化合物与化合物A和化合物C联合用药相比较,在抗流感病毒方面,具有更加优异的治疗效果和预防效果,由优异的治疗效果和预防效果分析,本发明这类化合物进入体内后,两个代谢组分起到了一定的协同作用。本发明所述的这类化合物可作为新型结构的抗病毒药物。
化合物A的结构如下:
化合物C结构如下:
定义:
除非另有说明,本文所用的下列术语和短语旨在具有下列含义。一个特定的术语或短语在没有特别定义的情况下不应该被认为是不确定的或不清楚的,而应该按照普通的含义去理解。当本文中出现商品名时,意在指代其对应的商品或其活性成分。
本发明的某些化合物可以以非溶剂化形式或者溶剂化形式存在,例如水 合物、乙醇合物形式。一般而言,溶剂化形式与非溶剂化的形式相当,都包含在本发明的范围之内。
术语“药学上可接受的”,是针对那些化合物、材料、组合物和/或剂型而言,它们在可靠的医学判断的范围之内,适用于与人类和动物的组织接触使用,而没有过多的毒性、刺激性、过敏性反应或其它问题或并发症,与合理的利益/风险比相称。
术语“药学上可接受的盐”是指本发明化合物的盐,由本发明发现的具有特定取代基的化合物与相对无毒的酸或碱制备。当本发明的化合物中含有相对酸性的功能团时,可以通过在纯的溶液或合适的惰性溶剂中用足够量的碱与这类化合物的中性形式接触的方式获得碱加成盐。药学上可接受的碱加成盐包括铝、钠、钾、钙、锰、铁、铵、有机氨或镁盐或类似的盐。当本发明的化合物中含有相对碱性的官能团时,可以通过在纯的溶液或合适的惰性溶剂中用足够量的酸与这类化合物的中性形式接触的方式获得酸加成盐。药学上可接受的酸加成盐的实例包括无机酸盐,所述无机酸包括例如盐酸、氢溴酸、硝酸、碳酸,碳酸氢根,磷酸、磷酸一氢根、磷酸二氢根、硫酸、硫酸氢根、氢碘酸、亚磷酸等;以及有机酸盐,所述有机酸包括如乙酸、丙酸、异丁酸、马来酸、丙二酸、苯甲酸、琥珀酸、辛二酸、反丁烯二酸、乳酸、扁桃酸、邻苯二甲酸、苯磺酸、对甲苯磺酸、柠檬酸、酒石酸和甲磺酸等类似的酸;还包括氨基酸(如精氨酸等)的盐,以及如葡糖醛酸等有机酸的盐。本发明的某些特定的化合物含有碱性和酸性的官能团,从而可以被转换成任一碱或酸加成盐。
术语“烷基”表示饱和的脂烃基,包括直链和支链基团烷基可以是取代的或未取代的。当是取代的烷基时,该取代基优选是一或多个,更优选1-3个,最优选1或2个取代基。
术语“烯基”表示含不饱和的碳碳双键的脂烃基,包括直链和支链基团烷基 可以是取代的或未取代的。碳碳双键可以是一或多个。
术语“环烷基”表示全部为碳的单环或稠合的环(“稠合”环意味着系统中的每个环与系统中的其它环共享毗邻的一对碳原子)基团,其中一个或多个环不具有完全连接的π电子系统,环烷基的实例(不局限于)为环丙烷、环丁烷、环戊烷、环戊烯、环己烷、金刚烷、环己二烯、环庚烷和环庚三烯。环烷基可为取代的和未取代的。
术语“芳基”表示1至12个碳原子的全碳单环或稠合多环基团,具有完全共轭的π电子系统。芳基的非限制性实例有苯基、萘基和蒽基。芳基可以是取代的或未取代的。当被取代时,取代基优选为一个或多个,更优选为一个、两个或三个,进而更优选为一个或两个。
术语“芳基烃基”表示被芳基取代的烃基。
术语“杂芳基”表示多个原子的单环或稠合环基团,含有一个、两个、三个或四个选自N、O或S的环杂原子,其余环原子是C,另外具有完全共轭的π电子系统。未取代的杂芳基地非限制性实例有吡咯、呋喃、噻吩、咪唑、噁唑、噻唑、吡唑、嘧啶、喹啉、异喹啉、嘌呤、四唑、三嗪和咔唑。
术语“烷氧基”表示烷基与氧相连的基团,这里的烷基可以直链、支链或环烷基。
术语“羟基”表示-OH基团.
术语“氨基”表示-NH
2基团。
术语“羧基”表示-COOH基团。
术语“卤素”表示氟、氯、溴或碘。
术语“药学上可接受的载体”是指能够递送本发明有效量活性物质、不干扰活性物质的生物活性并且对宿主或者患者无毒副作用的任何制剂或载体介质代表性的载体包括水、油、蔬菜和矿物质、膏基、洗剂基质、软膏基质等。这些基质包括悬浮剂、增粘剂、透皮促进剂等。
术语“立体异构体”指具有同一化学构成,但是原子或基团在空间的排列不同的化合物。
本申请书中提到的数字范围,例如“C1-C8”,是指该基团可以含1个碳原子、2个碳原子、3个碳原子等,直至包括8个碳原子。
图1表示的是抗流感病毒(H1N1)治疗性给药试验结果。
图2表示的是抗流感病毒(H1N1)预防性给药试验结果。
下面的实施例中提供了本发明的化合物的许多示例性制备方法。下面通过实施例对本发明进行详细描述,但并不意味着对本发明任何不利限制。本文已经详细地描述了本发明,其中也公开了其具体实施例方式,对本领域的技术人员而言,在不脱离本发明精神和范围的情况下针对本发明具体实施方式进行各种变化和改进将是显而易见的。本发明的某些化合物能够用作制备本发明的其它化合物用的中间体,所有化合物的结构均经液质或核磁确定。
本申请的实施例中的原料均通过商业途径购买。
实施例1:化合物PY-01的合成
反应式:
制备方法:
步骤1:化合物PY-0102的制备:
反应瓶中依次加入四氢呋喃(300ml)、PY-01-SM2(31.8g,100mmol)、4-二甲氨基吡啶(DMAP,18.33g,150momol),溶解后加入1-乙基-(3-二甲基氨基丙基)碳酰二亚胺(EDC,18.63g,120mmol)和化合物PY-01-SM1(28.43g,100mmol),升温至70℃,搅拌反应,TLC监控反应完毕,体系降温,蒸干,加入乙酸乙酯200ml,水100ml,分出有机相,再次水洗两次,干燥,减压蒸干,剩余物过柱纯化,得产物PY-0102(44.34g),收率75.8%。ESI-MS(+):m/z=585.16。
步骤2:化合物PY-0101的制备:
反应瓶中加入化合物PY-0102(44.00g,75.2mmol)、N,N-二甲基甲酰胺(250ml)、DIPEA(19.44g,150.4mmol),溶解后加入PyBroP(38.55g,82.7mmol),体系室温搅拌30min后加入盐酸羟胺(62.71g,90.24mmol),40~50℃反应4~6h,TLC检测反应完毕,降温,加水,乙酸乙酯萃取3次,合并有机相,水洗两次,减压蒸干,剩余物用甲基叔丁基醚/正庚烷重结晶,得产物PY-0101(39.00g),收率86.4%。ESI-MS(+):m/z=600.17。
步骤3:化合物PY-01的制备:
反应瓶中加入PY-0101(38.00g,63.3mmol)和甲酸(500ml),体系室温反应20小时。反应结束,减压浓缩,剩余物用异丙醇/甲基叔丁基醚重结晶,得化合物PY-01(29.21),收率82.4%。ESI-MS(+):m/z=560.2。1H NMR(DM SO-D6,500MHz):δ10.02(s,1H),9.49(s,1H),7.72-7.75(m,4H),7.63-7.64(d,2H),6.94-6.96(d,2H),6.78-6.80(d,1H),5.71-5.72(d,1H),5.46-5.48(d,1H),5.32-5.33(d,1H),5.20-5.21(d,1H),4.28-4.36(m,2H),3.97(s,1H),3.89-3.92(m,1H),3.78-3.79(d,1H),1.64-1.66(d,6H)。
实施例2:化合物PY-02的合成
反应式:
制备方法:
步骤1:化合物PY-0201的制备
参考实施例1步骤1的制备,用化合物PY-0101替换化合物PY-01-SM1,制备得化合物PY-0201(13.21g),收率73.5%。ESI-MS(+):m/z=900.22。
步骤2:化合物PY-02的制备
参考实施例1步骤3的制备,用化合物PY-0201替换化合物PY-0101,制备得化合物PY-02(10.14g),收率83.2%。ESI-MS(+):m/z=860.19。
实施例3:化合物PY-03的合成
反应式:
制备方法:
步骤1:化合物PY-0303的制备
氮气保护下,三颈烧瓶中加入化合物PY-03-SM3(25.0g,102.0mmo1)和 500ml二氯甲烷。将所得溶液冷却至0℃,并依次加入DMAP(1.3g,10.6mmol)和咪唑(27.9g,409.0mmo1)。在10分钟内加入TBSCl(61.7g,40.0mmol),并将得到的混合物温热至环境温度并搅拌18小时。体系中加入300mL水,室温下搅拌2小时,分液,水相用二氯甲烷萃取3次,合并的有机层用盐水洗涤,经硫酸钠干燥,过滤并减压浓缩,剩余物过柱纯化,得化合物PY-0303(43.4g),收率72.5%。ESI-MS(+):m/z=587.33。
步骤2:化合物PY-0302的制备
在1L圆底烧瓶中装入化合物PY-0303(28.0g,47.7mo1)和二氯甲烷(700mL)。使用冰浴将溶液冷却至0℃;依次加入DMAP(0.583g,4.77mmo1)和N,N-二异丙基乙胺(30.9g,239mmo1)。将2,4,6-三异丙基苯基-1-磺酰氯(28.9g,95mmol)缓慢添加到烧瓶中,加完后,将烧瓶温热至环境温度并搅拌18小时。体系冷却至0℃,滴加N,N二异丙基乙胺(24.6g,19lmol),然后立刻加入固体盐酸羟胺(13.26g,191mmol)。将混合物温热至室温,并搅拌3小时。用水(200mL)淬灭反应,并分离得到的层。将含水层用二氯甲烷(200mL)萃取,并将合并的有机物用盐水洗涤,用硫酸钠干燥,减压浓缩,所得剩余物过柱纯化,得到化合物PY-0302(20.0g),收率69.5%。ESI-MS(+):m/z=602.34。
步骤3:化合物PY-0301的制备
参考实施例1步骤1的制备,用化合物PY-0302替换化合物PY-01-SM1,制备得化合物PY-0301(18.6g),收率76.2%。ESI-MS(+):m/z=902.40。
步骤4:化合物PY-03的制备
三口瓶中加入化合物PY-0301(17.5g,19.4mol)和四氢呋喃(50mL)然后加入三乙胺三氢氟酸盐(3.1g,19.4mmo1),并将混合物在环境温度下搅拌18小时。将混合物在减压下浓缩,并将残留物溶解在最少量的MeOH中,将该溶液缓慢地添加到含有快速搅拌的二氯甲烷(50mL)的锥形烧瓶中,将混合 物在室温下搅拌15分钟。过滤,并用二氯甲烷和石油醚重结晶,得到标题化合物PY-03(7.65g),收率70.5%。ESI-MS(+):m/z=560.25。1H NMR(DMS O-D6,400MHz):δ11.34-11.35(s,1H),10.79-10.80(s,1H),7.70-7.74(m,4H),7.61-7.63(d,2H),7.48-7.51(d,1H),6.94-6.96(d,2H),5.72-5.78(m,2H),5.32-5.34(d,1H),5.02-5.08(d,2H),3.96-4.04(m,2H),3.83-3.84(m,1H),3.55(s,2H),1.76(s,3H),1.69(s,3H)。
实施例4:化合物ZJT1的合成
反应式:
制备方法:
步骤1:化合物ZJT1-03的制备
三口瓶中加入质量分数为80%甲胺溶液500ml,苯甲醚(36.4g,0.34mol),氯化亚铜(35.6g,0.36mol),控制溶液温度35℃,滴加对溴苯甲酰胺(101.9g,0.35mol),加完后升高溶液温度至45℃,维持搅拌速度反应7h,降低溶液温度至30℃,将反应液倒入至质量分数为30%亚硫酸氢钠溶液中,维持溶液温度在0~5℃,分出有机层,水层用甲胺溶液提取6次,合并有机层后,蒸出甲胺,得化合物ZJT1-03,备用。
步骤2:化合物ZJT1-02的制备
上述化合物ZJT1-03备用产物中加入己烷300m1,升温至60℃,加入氯化亚铜(59.4g,0.6mol),回流反应2h,蒸岀己烷,降低溶液温度至5℃,加入质量分数为60%碳酸氢钾溶液200ml,搅拌2h,过滤,硫酸钾溶液洗涤,得化合物ZJT1-02(79.2g),收率84.1%。ESI-MS(+):m/z=276.98。
步骤3:化合物ZJT1的制备
三口瓶中加入丙酮(120g,2.07mol)、化合物ZJT1-02(59.6g,0.21mol)搅拌约10分钟,加入氢氧化钠(60.0g,1.5mol),20~30℃搅拌下,滴加氯仿(45ml),氯仿滴加完毕后,在20~30℃保温1.5h,然后升温至回流3.5h。减压蒸出有机溶剂,向剩余物中加入100ml适量水和130ml甲苯,滴加36%盐酸(约60g),将料液酸化至p=3.5~4.5,然后再加入100ml,体系冷却至室温后搅拌2h,过滤,干燥得化合物ZJT1(66.5g),收率87.2%。ESI-MS(-):m/z=361.01。
实施例5:化合物ZJT2的合成
反应式:
制备方法:
参考实施例4各步骤的操作工序,将起始物料用对硝基苯甲酰胺替换对溴苯甲酰胺,得到化合物ZJT2(55.2g),收率85.8%。ESI-MS(-):m/z=328.09。
实施例6:化合物ZJT3的合成
反应式:
制备方法:
参考实施例4各步骤的操作工序,将起始物料用对氨基苯甲酰胺替换对溴苯甲酰胺,得到化合物ZJT3(51.9g),收率86.1%。ESI-MS(-):m/z=298.12。
实施例7:化合物ZJT4的合成
反应式:
制备方法:
参考实施例4各步骤的操作工序,将起始物料用3-氯苯甲酰胺替换对溴苯甲酰胺,得到化合物ZJT4(57.6g),收率82.9%。ESI-MS(-):m/z=317.07。
实施例8:化合物ZJT5的合成
反应式:
制备方法:
参考实施例4各步骤的操作工序,将起始物料用3,4-二氯苯甲酰胺替换对溴苯甲酰胺,得到化合物ZJT5(46.1g),收率79.6%。ESI-MS(-):m/z=351.03。
实施例9:化合物ZJT6的合成
反应式:
制备方法:
参考实施例4各步骤的操作工序,将起始物料用对甲氧基苯甲酰胺替换对溴苯甲酰胺,得到化合物ZJT6(31.3g),收率87.1%。ESI-MS(-):m/z=313.12。
实施例10:化合物ZJT7的合成
反应式:
制备方法:
参考实施例4各步骤的操作工序,将起始物料用3,4,5-三甲氧基苯甲酰胺替换对溴苯甲酰胺,得到化合物ZJT7(32.6g),收率84.3%。ESI-MS(-):m/z=373.14。
实施例11:化合物PY-ZJT8的合成
反应式:
制备方法:
参考实施例4各步骤的操作工序,将起始物料用3-(三氟甲基)苯甲酰胺替换对溴苯甲酰胺,得到化合物ZJT8(36.8g),收率81.1%。ESI-MS(-):m/z=351.09。
实施例12:化合物PY-ZJT9的合成
反应式:
制备方法:
将化合物PY-01-SM2(21.5g,67.5mmol)、水(300mL)、二氯甲烷(300mL)、四丁基硫酸氢铵(2.3g,6.75mmol)和碳酸氢钠(22.7g,270mmol)装入三口瓶中。室温下,滴加氯甲基氯磺酸盐(13.5g,81.7mmol),并在室温下搅拌反应过夜。分离有机层和水层,并用二氯甲烷(300mL)萃取水层。合并有机相,干燥、浓缩,过柱纯化(0至5%的乙酸乙酯/己烷梯度洗脱),得化合物ZJT9(18.7g),收率75.4%。
实施例13:化合物PY-04的合成
反应式:
制备方法:
参考实施例1各步骤的操作工序,用化合物ZJT1替换化合物PY-01-SM2做为起始物料,得到化合物PY-04(10.8g),总收率51.1%。ESI-MS(+):m/z=604.09。
实施例14:化合物PY-05的合成
反应式:
制备方法:
参考实施例2各步骤的操作工序,用化合物ZJT1替换化合物PY-01-SM2做为起始物料,得到化合物PY-05(12.3g),总收率57.6%。ESI-MS(+):m/z=948.09。
实施例15:化合物PY-06的合成
反应式:
制备方法:
参考实施例1各步骤的操作工序,用化合物ZJT2替换化合物PY-01-SM2做为起始物料,得到化合物PY-06(14.1g),总收率46.9%。ESI-MS(+):m/z=571.16。
实施例16:化合物PY-07的合成
反应式:
制备方法:
参考实施例1各步骤的操作工序,用化合物ZJT3替换化合物PY-01-SM2做为起始物料,得到化合物PY-07(13.6g),总收率48.5%。ESI-MS(+):m/z=541.19。
实施例17:化合物PY-08的合成
反应式:
制备方法:
步骤1:化合物PY-0804的制备:
氮气保护下将PY-01-SM2(1.91g,6mmol)加入至二氯甲烷(20mL)中,冷却至0℃,缓慢加入氯化亚砜(0.86g,7.2mmol),加入完毕后置于室温搅拌反应2.0h。体系浓缩至干,剩余物用甲苯(10mL×3)带除剩余的氯化亚砜,剩余物为化合物PY-0804,不做处理,备用;
步骤2:化合物PY-0803的制备:
将二氯甲烷(25mL)加入到步骤1所得剩余物(化合物PY-0804,6mmol)中,然后将上述混合物缓慢加入到溶有三氯化铝(0.48g,3.6mmol)的二氯甲烷溶液(20mL)中,加入完毕,室温搅拌20分钟。体系降温至0℃,在10分钟内逐滴添加乙醛(0.27g,6mmolg)。反应混合物在室温下搅拌1小时,体系逐渐添加到剧烈搅拌的冰水浆中。用二氯甲烷萃取3次,合并有机相,用冰水洗涤2次,分出有机相,无水硫酸钠干燥,过滤,滤液减压浓缩,剩余物通过柱色谱纯化得到化合物PY-0803(1.11g),收率48.7%。ESI-MS(+):m/z=381.06。
步骤3:化合物PY-0802的制备:
反应瓶中加入化合物PY-01-SM1(0.56g,2.0mmol),三乙胺(0.31g,3mmol)和化合物PY-0803(0.92g,2.4mmol),加入的N,N-二甲基甲酰胺(50mL),体系加热至50℃,搅拌24小时。降温至室温,加水搅拌,过滤,得到粗品,过硅胶柱纯化得到化合物PY-0802(0.96g),收率76.4%,ESI- MS(+):m/z=628.20。
步骤4:化合物PY-0801的制备:
反应瓶中加入化合物PY-0802(0.47g,0.75mmol)、N,N-二甲基甲酰胺(25ml)、DIPEA(0.20g,1.50mmol),溶解后加入PyBroP(0.39g,0.83mmol),体系室温搅拌30min后加入盐酸羟胺(0.63g,0.90mmol),40~50℃反应4~6h,TLC检测反应完毕,降温,加水,乙酸乙酯萃取3次,合并有机相,水洗两次,减压蒸干,剩余物过柱纯化,得产物化合物PY-0801(0.36g),收率74.5%。ESI-MS(+):m/z=644.19。
步骤5:化合物PY-08的制备:
反应瓶中加入化合物PY-0801(0.36g,0.56mmol)和甲酸(10mL),体系室温反应20小时。反应结束,减压浓缩,剩余物过柱纯化,得化合物PY-08(0.23g),收率68.7%,ESI-MS(+):m/z=604.16。1H NMR(DMSO-D6,400MHz):δ11.32-11.33(s,1H),10.77-10.78(s,1H),7.71-7.76(m,4H),7.59-7.61(d,2H),7.45-7.49(d,1H),6.91-6.94(d,2H),6.61(m,4H),5.70-5.75(m,2H),5.29-5.31(d,1H),5.01-5.06(d,2H),3.94-4.03(m,2H),3.81-3.83(m,1H),3.53(s,2H),1.72(d,3H),1.70(s,6H)。
实施例18:化合物PY-09的合成
反应式:
制备方法:
参考实施例3中步骤3和步骤4的操作工序,用化合物ZJT5替换化合物PY-01-SM2,得到化合物PY-09(9.3g),总收率50.1%。ESI-MS(+):m/z=592.12。
实施例19:化合物PY-10的合成
反应式:
制备方法:
参考实施例3中步骤3和步骤4的操作工序,用化合物ZJT6替换化合物PY-01-SM2,得到化合物PY-10(19.4g),总收率55.3%。ESI-MS(+):m/z=554.21。
实施例20:化合物PY-11的合成
反应式:
制备方法:
参考实施例1中步骤1和步骤2操作工序,用化合物ZJT7替换化合物PY-01-SM2,制备化合物PY-1102;
参考实施例2的各步骤操作工序,分别用化合物ZJT7替换化合物PY-01-SM2,化合物PY-1102替换化合物PY-0101,制备得化合物PY-11(5.7g),总收率35.3%。ESI-MS(+):m/z=972.33。
实施例21:化合物PY-24的合成
反应式:
制备方法:
参考实施例1各步骤的操作工序,用化合物ZJT8替换化合物PY-01-SM2做为起始物料,得到化合物PY-24(5.1g),总收率45.9%。ESI-MS(+):m/z=594.16。
实施例22:化合物PY-26的合成
反应式:
制备方法:
步骤1:化合物PY-2602的合成
参考实施例1中步骤3操作工序,制备得化合物PY-2602(6.1g),收率78.3%。ESI-MS(+):m/z=545.12。
步骤2:化合物化合物PY-2601
三口瓶中加入化合物PY-2602(5.6g,10.24mol)和乙酸乙酯(120mL)。搅拌下,将三乙胺(5.2g,51.12mol)和DMAP(0.063g,5.12mmol)加入到上述体系中。降温至10℃以下,并在5分钟内将三氟乙酸酐(6.45g,30.72mmol)缓慢添加到上述体系中。加入期间体系放热。加入完毕,体系室温搅拌1h,TLC检测反应完毕。体系用40mL水淬灭反应,在室温下搅拌20分钟。分离各层,并将有机物用水(2×50mL)、饱和的碳酸氢盐水溶液(50mL×2)、水(50mL)、盐水(50mL×2)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,剩余物为化合物PY-2601。无需进一步纯化用于下一步。ESI-MS(+):m/z=737.09。
步骤3:化合物PY-26的制备
参考实施例1中步骤2操作工序,制备得化合物PY-26(2.2g),收率83.6%。ESI-MS(+):m/z=754.12。
实施例23:化合物PY-27的合成
反应式:
制备方法:
步骤1:化合物PY-2702的合成
反应瓶中加入化合物PY-01-SM1(14.2g,50.0mmol),三乙胺(75.9g,75.0mmol)和ZJT9(36.7g,100.0mmol),加入500ml的N,N-二甲基甲酰胺,体系加热至50℃,搅拌24小时。降温至室温,加水搅拌,过滤,得到粗品,过硅胶柱纯化得到化合物PY-2702(17.2g),收率55.8%,ESI-MS(+):m/z=615.17。
步骤2:化合物化合物PY-2701
参考实施例1中步骤2的操作工序,制备得化合物PY-2701(10.1g),收率82.3%。ESI-MS(+):m/z=630.18。
步骤3:化合物PY-27的制备
参考实施例1中步骤3操作工序,制备得化合物PY-27(5.3g),收率79.6%。ESI-MS(+):m/z=590.15。
实施例24:化合物PY-28的合成
反应式:
制备方法:
步骤1:化合物PY-2801的合成
参考实施例23中步骤1的操作工序,制备得化合物PY-2801(12.2g),收率51.4%,ESI-MS(+):m/z=932.41。
步骤2:化合物化合物PY-28
参考实施例3中步骤4的操作工序,制备得化合物PY-28(5.2g),收率68.3%。ESI-MS(+):m/z=590.15。
实施例25:化合物PY-34的合成
反应式:
制备方法:
步骤1:化合物PY-3404的制备:
氮气保护下将PY-01-SM2(1.91g,6mmol)加入至二氯甲烷(20mL)中,冷却至0℃,缓慢加入氯化亚砜(0.86g,7.2mmol),加入完毕后置于室温搅拌反应2.0h。体系浓缩至干,剩余物用甲苯(10mL×3)带除剩余的氯化亚砜,剩余物为化合物PY-3404,不做处理,备用;
步骤2:化合物PY-3403的制备:
将二氯甲烷(25mL)加入到步骤1所得剩余物(化合物PY-3404,6mmol)中,然后将上述混合物缓慢加入到溶有三氯化铝(0.48g,3.6mmol)的二氯甲烷溶液(20mL)中,加入完毕,室温搅拌20分钟。体系降温至0℃,在10分钟内逐滴添加乙醛(0.27g,6mmolg)。反应混合物在室温下搅拌1小时,体系逐渐添加到剧烈搅拌的冰水浆中。用二氯甲烷萃取3次,合并有机相,用冰水洗涤2次,分出有机相,无水硫酸钠干燥,过滤,滤液减压浓缩,剩余物通过柱色谱纯化得到化合物PY-3403(1.11g),收率48.7%。ESI-MS(+):m/z=381.06。
步骤3:化合物PY-3402的制备:
反应瓶中加入化合物PY-01-SM1(0.56g,2.0mmol),三乙胺(0.31g,3mmol)和化合物PY-3403(0.92g,2.4mmol),加入的N,N-二甲基甲酰胺(50mL),体系加热至50℃,搅拌24小时。降温至室温,加水搅拌,过滤,得到粗品,过硅胶柱纯化得到化合物PY-3402(0.96g),收率76.4%,ESI-MS(+):m/z=628.20。
步骤4:化合物PY-3401的制备:
反应瓶中加入化合物PY-3402(0.47g,0.75mmol)、N,N-二甲基甲酰胺(25ml)、DIPEA(0.20g,1.50mmol),溶解后加入三吡咯烷基溴化鏻六氟磷酸盐(PyBroP,0.39g,0.83mmol),体系室温搅拌30min后加入盐酸羟胺(0.63g,0.90mmol),40~50℃反应4~6h,TLC检测反应完毕,降温,加水,乙酸乙酯萃取3次,合并有机相,水洗两次,减压蒸干,剩余物过柱纯化,得产物化合物PY-3401(0.36g),收率74.5%。ESI-MS(+):m/z=644.19。
步骤5:化合物PY-34的制备:
反应瓶中加入化合物PY-3401(0.36g,0.56mmol)和甲酸(10mL),体系室温反应20小时。反应结束,减压浓缩,剩余物过柱纯化,得化合物PY-34(0.23g),收率68.7%,ESI-MS(+):m/z=604.16。1H NMR(DMSO-D6,400 MHz):δ11.32-11.33(s,1H),10.77-10.78(s,1H),7.71-7.76(m,4H),7.59-7.61(d,2H),7.45-7.49(d,1H),6.91-6.94(d,2H),6.61(m,4H),5.70-5.75(m,2H),5.29-5.31(d,1H),5.01-5.06(d,2H),3.94-4.03(m,2H),3.81-3.83(m,1H),3.53(s,2H),1.72(d,3H),1.70(s,6H)。
实施例26:化合物PY-35的合成
反应式:
制备方法:
步骤1:化合物PY-3501的制备
参考实施例25步骤3的制备,用化合物PY-3401替换化合物PY-01-SM1,制备得化合物PY-3501(1.26g),收率69.5%。ESI-MS(+):m/z=988.27。
步骤2:化合物PY-35的制备
参考实施例25步骤5的制备,用化合物PY-3501替换化合物PY-3401,制备得化合物PY-35(0.19g),收率63.2%。ESI-MS(+):m/z=948.24。
实施例27:化合物PY-36的合成
反应式:
制备方法:
步骤1:化合物PY-3603的制备
氮气保护下,将化合物PY-03-SM3(12.5g,51.0mmol)和二氯甲烷(250mL)加入三口瓶。将所得溶液冷却至0℃,并依次加入4-二甲氨基吡啶(DMAP,0.70g,5.7mmol)和咪唑(14.0g,205.6mmol)。在10分钟内加入叔丁基二甲基氯硅烷(TBSC1,30.9g,205.0mmol),并将得到的混合物温热至环境温度并搅拌18小时。体系中加入水,室温下搅拌2小时,分液,水相用二氯甲烷萃取3次,合并的有机层用盐水洗涤,经硫酸钠干燥,过滤并减压浓缩,剩余物过柱纯化,得化合物PY-3603(21.1g),收率70.6%。ESI-MS(+):m/z=587.33。
步骤2:化合物PY-3602的制备
将化合物PY-3603(14.0g,23.9mmol)和二氯甲烷(350mL)加入三口瓶。使用冰浴将溶液冷却至0℃。依次加入DMAP(0.29g,0.24mmol)和N,N-二异丙基乙胺(15.5g,120mmol)。将2,4,6-三异丙基苯-1-磺酰氯(14.5g,47.5mmol)缓慢添加到烧瓶中,加完后,将烧瓶温热至环境温度并搅拌18小时。体系冷却至0℃,滴加N,N二异丙基乙胺(12.3g,95.5mmol),然后立刻加入固体 盐酸羟胺(6.63g,95.5mmol)。将混合物温热至室温,并搅拌3小时。用水淬灭反应,并分离得到的层。将含水层用二氯甲烷萃取,并将合并的有机物用盐水洗涤,用硫酸钠干燥,减压浓缩,所得剩余物过柱纯化,得到化合物PY-3602(9.41g),收率65.4%。ESI-MS(+):m/z=602.34。
步骤3:化合物PY-3601的制备
参考实施例25步骤3的制备,用化合物PY-3602替换化合物PY-01-SM1,制备得化合物PY-3601(10.1g),收率71.3%。ESI-MS(+):m/z=946.42。
步骤4:化合物PY-36的制备
三口瓶中加入化合物PY-0301(9.5g,1.0mmol)和四氢呋喃(100mL)然后加入三乙胺三氢氟酸盐(1.61g,1.0mmol),并将混合物在环境温度下搅拌18小时。将混合物在减压下浓缩,并将残留物溶解在最少量的甲醇中,将该溶液缓慢地添加到含有快速搅拌的二氯甲烷中,将混合物在室温下搅拌15分钟。过滤,并用二氯甲烷和石油醚重结晶,得到标题化合物PY-36(4.05g),收率67.1%。ESI-MS(+):m/z=604.16。
实施例28:化合物ZJT10的合成
反应式:
制备方法:
步骤1:化合物ZJT10-02的制备:
氮气保护下,将嘧啶-5-D(11.31g,0.1mol)、BSA(40.7g,0.2mol)和无水乙腈(250mL)加入反应瓶,加热至80℃,搅拌反应30min;降至室温,加入四乙酰核糖(63.3g,0.2mol),滴加TMSOTf(44.5g,0.2mol),加入完毕,升温至80℃,反应2小时,冷至室温,减压蒸出乙腈;剩余物加入乙酸乙酯,用饱和 碳酸氢钠水溶液洗涤2次,分出有机相,饱和食盐水洗涤2次,无水硫酸钠干燥,过滤,减压浓缩,剩余物柱层析,得化合物ZJT10-02(31.6g),收率85.2%。ESI-MS(+):m/z=372.13。
步骤2:化合物ZJT10-01的制备:
将化合物ZJT10-02(31.0g,0.084mol)和7M的氨/甲醇溶液(500mL,3.5mol)加入反应瓶,室温搅拌36小时,蒸出溶剂,剩余物柱层析得化合物ZJT10-01(15.5g),收率75.2%。ESI-MS(+):m/z=246.10。
步骤3:化合物ZJT10的制备
将化合物ZJT10-01(15.0g,0.061mol)溶于丙酮(300mL)中,缓慢加入2,2-二甲氧基丙烷(31.8g,0.305mol),加入完毕,搅拌10分钟后,缓慢加入浓硫酸(2.0g,0.020mol),搅拌30分钟;向体系加入饱和碳酸氢钠淬灭,减压蒸出溶剂,剩余物柱层析得化合物ZJT10(11.5g),收率66.1%。ESI-MS(+):m/z=286.20。
实施例29:化合物ZJT11的合成
反应式:
制备方法:
参考实施例1的操作工序,用尿嘧啶-2D替换嘧啶-5-D作为起始物料,得化合物ZJT11(10.2g),总收率40.1%。ESI-MS(+):m/z=287.22。
实施例30:化合物ZJT12的合成
反应式:
制备方法:
步骤1:化合物ZJT12-01的制备
氮气保护下,室温下,将PY-01-SM1(6.3g,22.0mmol)和二氯甲烷(200mL)加入反应瓶。然后搅拌下依次将重铬酸吡啶鎓(16.6g,44.1mmol)、乙酸酐(22.5g,220mmol)和叔丁醇(16.3g,220mmol)加入体系。上述体系室温搅拌24小时,用水洗涤,分出水相,用二氯甲烷萃取2次,合并有机相,饱和食盐水洗涤2次,无水硫酸钠干燥,过滤,浓缩,剩余物柱层析得化合物ZJT12-01(5.5g),收率70.5%。ESI-MS(+):m/z=355.15。
步骤2:化合物ZJT12的制备
氮气保护下,室温下,将化合物ZJT12-01(5.4g,15.2mmol)加入乙醇-D1(200mL)中,搅拌下,将硼氘化钠-D4(2.5g,60.8mmol)一次性加入。加入完毕,室温搅拌1小时,加热至55℃持续7小时,然后室温搅拌过夜。将体系降温至0℃,用乙酸-D1淬灭,减压蒸干,得剩余物柱层析,得化合物ZJT12(3.0g),收率68.2%。ESI-MS(+):m/z=287.15
实施例31:化合物PY-49的合成
反应式:
制备方法:
步骤1:化合物PY-4902的制备
反应瓶中依次加入四氢呋喃(30mL)、PY-01-SM2(3.18g,10mmol)、4- 二甲氨基吡啶(DMAP,1.83g,15mmol),溶解后加入1-乙基-(3-二甲基氨基丙基)碳酰二亚胺(EDC,1.86g,12mmol)和ZJT10(2.85g,10mmol),升温至70℃,搅拌反应,TLC监控反应完毕,体系降温,蒸干,剩余物加入乙酸乙酯和水,分出有机相,再次水洗两次,干燥,减压蒸干,剩余物过柱纯化,得产物PY-4902(4.2g),收率71.7%。ESI-MS(+):m/z=586.20。
步骤2:化合物PY-4901的制备
反应瓶中加入化合物PY-4902(4.1g,7.0mmol))、N,N-二甲基甲酰胺(25mL)、N,N-二异丙基乙胺(DIPEA,1.81g,14.0mmol),溶解后加入三吡咯烷基溴化鏻六氟磷酸盐(PyBroP,3.59g,7.7mmol),体系室温搅拌30min后加入盐酸羟胺(0.59g,8.4mmol),40~50℃反应4~6h,TLC检测反应完毕,降温,加水,乙酸乙酯萃取3次,合并有机相,水洗两次,减压蒸干,剩余物柱层析得产物PY-4901(2.93g),收率69.6%。ESI-MS(+):m/z=601.17。
步骤6:化合物PY-49的制备
反应瓶中加入PY-4901(2.9g,4.83mmol)和甲酸(50mL),体系室温反应20小时。反应结束,减压浓缩,剩余物用异丙醇/甲基叔丁基醚重结晶,得化合物PY-49(2.17g),收率80.1%,ESI-MS(+):m/z=561.14。1H NMR(DM SO-D6,500MHz):δ10.05(s,1H),9.44(s,1H),7.74-7.77(m,4H),7.65-7.66(d,2H),6.96-6.98(d,2H),6.79-6.81(d,1H),5.73-5.75(d,1H),5.33-5.34(d,1H),5.22-5.23(d,1H),4.29-4.37(m,2H),3.98(s,1H),3.91-3.95(m,1H),3.79-3.80(d,1H),1.65-1.67(d,6H)。
实施例32:化合物PY-50的制备
反应式:
制备方法:
参考实施例31的操作工序,用ZJT12替换ZJT10作为起始物料,得化合物PY-50(1.21),总收率42.2%。ESI-MS(+):m/z=562.18。
实施例33:化合物PY-51的制备
反应式:
制备方法:
参考实施例31的操作工序,用ZJT12替换ZJT10作为起始物料,得化合物PY-51(1.52),总收率38.5%。ESI-MS(+):m/z=562.20。
实施例34:化合物PY-52的制备
反应式:
制备方法:
步骤1:化合物PY-5203的制备
氮气保护下,将化合物ZJT10-01(2.5g,10.2mmol)和二氯甲烷(50mL)加入反应瓶,冷却至0℃;然后依次加入DMAP(0.13g,1.02mmol)和咪唑(2.8g,40.9mmol)。在10分钟内加入叔丁基二甲基氯硅烷(TBSCl,6.17g,4.0mmol),并将得到的混合物温热至环境温度并搅拌18小时。体系中加入水(30mL),室温下搅拌2小时,分液,水相用二氯甲烷萃取3次,合并的有机层用盐水洗涤,经硫酸钠干燥,过滤并减压浓缩,剩余物过柱纯化,得化合物PY-5203(4.14g),收率69.0%。ESI-MS(+):m/z=588.33。
步骤2:化合物PY-5202的制备
将化合物PY-5203(4.00g,6.8mmol)和二氯甲烷(100mL)加入反应瓶,搅拌降温至0℃,然后依次加入DMAP(0.083和g,0.68mmol)和N,N-二异丙基乙胺(4.41g,34.1mmol)加入上述体系,搅拌下,将2,4,6-三异丙基苯-1-磺酰氯(4.13g,13.6mmol)缓慢添加到烧瓶中,加完后,室温搅拌18小时。体系再次冷却至0℃,滴加N,N-二异丙基乙胺(3.51g,27.2mmol),然后立刻加入固体盐酸羟胺(1.9g,27.3mmol)。将混合物温热至室温,并搅拌3小时。用水淬灭反应,分液,将水层用二氯甲烷萃取2次,合并有机相,用盐水洗涤,硫酸钠干燥,减压浓缩,所得剩余物过柱纯化,得到化合物PY-5202(2.70g),收率65.9%。ESI-MS(+):m/z=603.34。
步骤3:化合物PY-5201的制备
参考实施例31步骤1的制备,用化合物PY-5202替换化合物ZJT10,制备得化合物PY-5201(2.22g),收率66.5%。ESI-MS(+):m/z=903.43。
步骤4:化合物PY-52的制备
三口瓶中加入化合物PY-5201(1.75g,1.94mol)和四氢呋喃(20mL)然后加入三乙胺三氢氟酸盐(0.31g,1.94mmo1),并将混合物在环境温度下搅拌18小时。将混合物在减压下浓缩,剩余物柱层析得化合物PY-52(0.53g),收率48.7%。ESI-MS(+):m/z=561.16。
实施例35:化合物PY-54的制备
反应式:
制备方法:
参考实施例34的操作工序,用ZJT11-01替换ZJT10-01作为起始物料,得化合物PY-54(0.46),总收率16.2%。ESI-MS(+):m/z=562.20。
实施例36:化合物PY-55的制备
反应式:
制备方法:
参考实施例31步骤1和步骤3的操作工序,以化合物PY-4901为起始物料,制备得化合物PY-55(0.25g),总收率50.2%。ESI-MS(+):m/z=861.22。
实施例37:化合物PY-56的制备
反应式:
制备方法:
步骤1:化合物PY-5604的合成
氮气保护下将PY-01-SM2(3.82g,12mmol)加入至二氯甲烷(50mL)中,冷却至0℃,缓慢加入氯化亚砜(1.72g,14.4mmol),加入完毕后置于室温搅拌反 应2.0h。体系浓缩至干,剩余物用甲苯带除剩余的氯化亚砜3次,剩余物为化合物PY-5604,不做处理,备用;
步骤2:化合物PY-5603的合成
将二氯甲烷(50mL)加入到步骤1所得剩余物(化合物PY-5604,12mmol)中,然后将上述混合物缓慢加入到溶有三氯化铝(0.96g,7.2mmol)的二氯甲烷溶液(40mL)中,加入完毕,室温搅拌20分钟。体系降温至0℃,在10分钟内逐滴添加乙醛(0.54g,12mmol)。反应混合物在室温下搅拌1小时,体系逐渐添加到剧烈搅拌的冰水浆中。用二氯甲烷萃取3次,合并有机相,用冰水洗涤2次,分出有机相,无水硫酸钠干燥,过滤,滤液减压浓缩,剩余物通过柱色谱纯化得到化合物PY-5603(2.07g),收率45.2%。ESI-MS(+):m/z=381.06。
步骤3-步骤5:化合物PY-56的合成
参考实施例31各步骤的操作工序,用PY-5603替换PY-01-SM2作为起始物料,得化合物PY-56(1.12),三步总收率35.3%。ESI-MS(+):m/z=605.20。
按照与上述实施例同样的方法,使用市售化合物或由市售化合物适当合成的中间体化合物,合成了下列实施例化合物。
实施例38:稳定性试验
化合物PY-01、PY-02、PY-03、PY-12、PY-15、PY-18、PY-21、PY-34、PY-49,以及化合物A分别用0.5%羧甲基纤维素钠溶液和1.0%甲基纤维素溶液配置样品,将上述样品(口部密封)置于25.0℃的稳定性箱中,湿度37%,避光存放,HPLC(带有DAD检测器)检测第0天、3天、7天的稳定性。结果如表一。
表一 稳定性试验结果
结果表明,本发明系列化合物稳定性比对照品化合物A更好。
实施例39:体外抗流感病毒活性以及细胞毒性测定
待测化合物对MDCK的毒性测定:
取对数生长期的MDCK细胞接种于24孔细胞培养板,37℃,5%CO
2的培养箱中培养24h后先以不同稀释浓度的药物作用2h,然后用Hanks液液洗板3次,甩干后每孔加1ml含2%新生牛血清DMEM维持液维持生长,37℃,5%CO
2的培养箱中培养。观察7天内细胞病变程度(CPE),用Reed-Muench法分别计算样品对细胞的半数有毒浓度(TC
50)。
待测化合物的抗流感病毒活性测定:
取对数生长期的MDCK细胞接种于24孔板中每孔约含细胞(1×10
4个),37℃,5%CO
2培养箱中培养。24h后先用病毒液(H1N1,A/WSN/33)感染细胞,用Hanks液液洗涤2次,再以药物稀释液作用细胞,用Hanks液液洗涤3次,最后用含2%新生牛血清的DMEM维持液在37℃,5%CO
2培养箱中培养。分别在培养后1、2、3、4、5、6、7天时在倒置显微镜下观察细胞病变程度(CPE),用Reed-Muench法分别计算样品对细胞的对病毒的半数抑制浓度(IC
50),然后计算选择指数(SI),SI的计算方法为SI=TC
50/IC
50。结果见表二。
表二 体外抗流感病毒活性数据
样品编号 | TC 50(μmol/L) | IC 50(μmol/L) | SI |
化合物A | 133.26 | 1.18 | 113 |
PY-01 | >200 | 0.15 | >1333 |
PY-02 | 145.22 | 0.35 | 415 |
PY-03 | 199.03 | 0.43 | 463 |
PY-12 | 169.82 | 0.52 | 327 |
PY-15 | 157.98 | 0.36 | 439 |
PY-18 | 158.25 | 0.44 | 360 |
PY-21 | 174.58 | 0.48 | 364 |
PY-34 | 188.35 | 0.54 | 349 |
PY-49 | >200 | 0.22 | >909 |
实验结果表明,所检测的本发明化合物样品与公开的化合物A相比较,对流感病毒(H1N1)有更好的抑制活性、更低的细胞毒性,且选择指数更高。
实施例40:体外抗新型冠状病毒活性(EC
50)测定
Vero E6细胞以一定密度接种到微孔板中并于5%CO
2、37℃培养箱中培养过夜。第二天,加入倍比稀释的化合物(8个浓度点,三复孔)和SARS-CoV-2病毒(B.1.1.7(Alpha))。设置细胞对照(细胞,无化合物处理或病毒感染),病毒对照(细胞感染病毒,无化合物处理)。细胞于培养箱中培养3或4天。
化合物的抗病毒活性由不同浓度下的化合物对病毒引起的细胞病变效应的抑制率(%)表示。使用GraphPad Prism对化合物的抑制率进行非线性拟合分析,计算化合物的EC
50。结果见表三。
表三 体外抗新型冠状病毒活性数据
样品编号 | EC 50(μmol) |
化合物A | 1.62 |
PY-01 | 0.35 |
PY-02 | 0.58 |
PY-03 | 0.66 |
PY-12 | 0.79 |
PY-15 | 0.57 |
PY-18 | 0.66 |
PY-21 | 0.77 |
PY-34 | 0.82 |
PY-49 | 0.33 |
实验结果表明,所检测的本发明化合物样品与公开的化合物A相比较, 对SARS-CoV-2病毒(B.1.1.7(Alpha))有更好的抑制活性。
实施例41:化合物PY-01在大鼠体内的药代动力学特征评价
12只SD大鼠,雄性,180g-220g。饲养条件为室温:20~26℃,湿度:40-70%,光照明:暗=12h:12h;大鼠适应性饲养3天,期间自由摄食饮水。随机分为4组,每组3只。2个供试品(PY-01和化合物A)分别单次等摩尔口服灌胃给药和等摩尔尾静脉注射给药。于给药前一天下午5点开始禁食16-17h,给药4h后动物给食,全过程不禁水。
单次口服灌胃给药前给药后0.25h、0.5h、1h、2h、3h、4h、8h、24h或单次静脉注射给药前、给药后0.083h、0.25h、0.5h、1h、2h、4h、8h、24h取血。
每个采血时间点,经大鼠眼球取静脉血约300μL,加入冰水预冷的带有肝素钠的离心管中,并置于冰浴,静置后离心(4000rpm,10min),以50μL为单位体积分装,置于无菌EP管内,-80℃保存备用。尽快测定血浆中化合物B的浓度。采用HPLC(High Performance Liquid Chromatography)与LC/MS测定血浆中药物浓度,并使用非线性最小二乘法程序算出血浆中浓度-时间曲线下面积(AUC),算出药物在大鼠体内的生物利用度。
绝对生物利用度:F=AUClast-po/AUClast-iv×100%。结果见表四。
化合物B的结构如下:
表四 药代动力学结果
SD大鼠药代动力学实验结果表明,化合物PY-01具有更长的半衰期,口服给药后体内暴露量更大,其生物利用度是化合物A的近1.4倍。化合物PY-01给药后化合物B的Cmax低于化合物A给药,说明本发明化合物具有更好的安全范围。
实施例42:体内抗流感病毒治疗性给药试验
C57BL/6J小鼠30只,6-8周龄,SPF级别,雌性,随机分为6组,分别编号为组1、组2、组3、组4、组5和组6,每组5只。滴鼻接种半致死剂量100pfu的流感病毒(H1N1,A/WSN/33)病毒24h后,组1(溶媒组)灌胃给予0.5%的羧甲基纤维素钠溶液;组2灌胃给予对照药(等摩尔,17.33mg/kg的化合物A和19.01mg/kg的化合物C,联合用药);组3-组5分别灌胃给予试验药物(29.46mg/kg的PY-01、29.46mg/kg的PY-03、29.46mg/kg的PY-49);组6在滴鼻接种病毒48h后开始给予29.46mg/kg的PY-01。各组给药均为等摩尔给药,每天两次,组1-组5给药或溶媒4天,组6给药3天。于接种病毒后第5天处死动物,收取肺组织样品,匀浆处理后进行病毒滴度测定。结果如图1所示。
结果表明,感染病毒24h后用药,化合物PY-01、化合物PY-03和化合物PY-49均表现出了优秀的抗流感病毒(H1N1)效果,表现出比联合给药更强的抗流感病毒(H1N1)作用。化合物PY-01在感染病毒48h后也能够显著降低病毒的滴度。
实施例43:体内抗流感病毒(H1N1)预防性给药试验
BALB/c小鼠30只,6-8周龄,SPF级别,雌性,随机分为6组,分别编号为组1、组2、组3、组4、组5和组6,每组5只。各组均于-1天开始给药,第0天滴鼻接种100PFU的流感病毒(H1N1,A/Puerto Rico/8/1934),接种病毒当天给药后2小时接种病毒。其中,组1(溶媒组)灌胃给予0.5%的 羧甲基纤维素钠溶液;组2灌胃给予对照药(17.33mg/kg的化合物A和19.01mg/kg的化合物C,联合用药);组3-组5分别灌胃给予不同剂量的试验药物(PY-01的高、中、低剂量组:88.37mg/kg、29.46mg/kg、9.82mg/kg);组6灌胃给予试验药物PY-01的高剂量(88.37mg/kg)。各组均为等摩尔给药,每天一次,组1-5给药或溶媒5天,组6给药2天。于接种病毒后第4天处死动物,收取肺组织样品,匀浆处理后进行病毒滴度测定。结果如图2所示。
结果表明:与溶媒组相比,实验各组均表现出较低的病毒滴度;相同的给药天数时,与联合给药组相比,PY-01高剂量组和中剂量组的病毒滴度更低;与组3(高剂量的PY-01在接种病毒前给药2天,接种病毒后给药3天)相比,组6(高剂量的PY-01在接种病毒前给药2天接种病毒后不给药)的病毒滴度略大,但仍低于其它各组。这说明本发明化合物具有显著的流感病毒的预防作用。
虽然本发明已以较佳实施例揭示如上,然其并非用以限定本发明,任何本领域技术人员,在不脱离本发明的精神和范围内,当可作些许的修改和完善,因此本发明的保护范围当以权利要求书所界定的为准。
Claims (11)
- 一种如(I 0)所示的新型胞苷衍生物、互变异构体、立体异构体、同位素衍生物及其药学上可接受的盐:式(I 0)中,其中,n 1选自0、1、2或3;n 2选自1、2或3;R a和R b分别独立地选自羟基、被一个或多个基团A取代或未取代的下列基团:C1-C8烷基、C1-C8烷氧基、C2-C8烯基、C3-C8环烷基、C6-C18芳基、芳基氧基、芳基烷基、烷基芳基;R c和R d分别独立地选自氢、被一个或多个基团A取代或未取代的C1-C8的烷基;其中,n a选自0、1、2、3、4、或5;n b选自1、2、3、4、或5;n 3选自0、1、2、3、4、或5;n 4选自0、1、2、3、或4;R 5和R 6相同或不同,独立的选自氢、被一个或多个基团A取代或未取代的C1-C8烷基;或者R 5、R 6与其相连的碳成环烷基;R 7为氢、卤素、氨基、被一个或多个基团A取代或未取代的C1-C8烷基;其中,n 5分别独立的为0、1、2、3、4、或5;R 8选自H、羟基、硝基、卤素、被一个或多个基团A取代或未取代的下列基团:氨基、C1-C8烷基、C6-C18芳基、C1-C8烷氧基、氨基烷基、C1-C8烷基芳基、芳基羰基、C1-C8的烷基羰基氧基;R e和R f分别独立地选自氢、被一个或多个基团A取代或未取代的下列基团:C1-C8烷基、C3-C8环烷基、杂环烷基、C6-C18芳基、杂芳基、非芳香族杂环基;R X1、R X2、R X3、R X4、R X5、R X6、R X7和R X8分别独立地选自氢、氘;所述基团A为:羟基、羧基、氨基、卤素、氰基、醛基、硝基、三氟甲基、C3-C8的环烷基、C1-C8的烷氧基、氯苯羰基。
- 包含如权利要求1~6中任一项所述的新型胞苷衍生物、互变异构体、立体异构体、同位素衍生物及其药学上可接受的盐的药物组合物。
- 权利要求1~6中任一项所述的新型胞苷衍生物、互变异构体、立体异构体、同位素衍生物及其药学上可接受的盐,或者权利要求7所述的药物组合物在制备抗病毒药物中的应用。
- 权利要求8所述的应用,其中,所述的病毒,包括但不限:沙粒病毒科、丝状病毒科和冠状病毒科病毒等,包括但不限于腺病毒、鼻病毒、流感病毒、拉沙病毒、呼吸道合胞病毒、严重急性呼吸综合症病毒、副流感病毒、冠状病毒等。
- 权利要求9所述的应用,其中,所述的流感病毒和冠状病毒包括但不限于:甲型流感病毒、乙型流感病毒、SARS病毒、MERS病毒、COVID-19病毒等。
- 一种治疗或预防个体病毒感染的方法,包括对有相应需要的个体施用治疗有效量的权利要求1~6中任一项所述的新型胞苷衍生物、互变异构体、立体异构体、同位素衍生物及其药学上可接受的盐,或者权利要求7所述的 药物组合物;所述的病毒感染,包括但不限于如下病毒的感染:沙粒病毒科、丝状病毒科和冠状病毒科病毒等,包括但不限于腺病毒、鼻病毒、流感病毒、拉沙病毒、呼吸道合胞病毒、严重急性呼吸综合症病毒、副流感病毒、冠状病毒等。
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110992872.0 | 2021-08-27 | ||
CN202110992872 | 2021-08-27 | ||
CN202210347676 | 2022-04-01 | ||
CN202210347676.2 | 2022-04-01 | ||
CN202210651392 | 2022-06-10 | ||
CN202210651392.2 | 2022-06-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023025319A1 true WO2023025319A1 (zh) | 2023-03-02 |
Family
ID=85322493
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/115474 WO2023025319A1 (zh) | 2021-08-27 | 2022-08-29 | 一种新型的胞苷衍生物及其药物组合物和用途 |
Country Status (2)
Country | Link |
---|---|
CN (2) | CN115960148B (zh) |
WO (1) | WO2023025319A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11963967B2 (en) | 2020-10-16 | 2024-04-23 | Gilead Sciences, Inc. | Phospholipid compounds and uses thereof |
US12030904B2 (en) | 2023-04-14 | 2024-07-09 | Gilead Sciences, Inc. | Phospholipid compounds and uses thereof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024125604A1 (en) * | 2022-12-16 | 2024-06-20 | Suzhou Spring-Sea Bio-Pharmaceuticals Co. Ltd. | Diester derivatives of n4-hydroxycytidine and use thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104884462A (zh) * | 2012-10-29 | 2015-09-02 | 共晶制药股份有限公司 | 用于治疗病毒感染和癌症的嘧啶核苷及其单磷酸酯前药 |
CN107427529A (zh) * | 2014-12-26 | 2017-12-01 | 埃莫里大学 | N4‑羟基胞苷和衍生物及与其相关的抗病毒用途 |
CN111372592A (zh) * | 2017-12-07 | 2020-07-03 | 埃默里大学 | N4-羟基胞苷及衍生物和与其相关的抗病毒用途 |
CN111548384A (zh) * | 2020-03-29 | 2020-08-18 | 常州安蒂卫生物科技有限公司 | 用于抗新型冠状病毒治疗的被取代的n4-羟基胞苷衍生物及其前药 |
CN111971284A (zh) * | 2017-12-27 | 2020-11-20 | 埃默里大学 | 核苷和/或nadph氧化酶(nox)抑制剂作为髓样特异性抗病毒剂的联合模式 |
WO2021159044A1 (en) * | 2020-02-07 | 2021-08-12 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU205917B (en) * | 1989-09-29 | 1992-07-28 | Mitsubishi Chem Ind | Process for producing 6-substituted pyrimidine derivatives and antiviral pharmaceutical compositions containing them as active components |
US10874683B2 (en) * | 2016-03-10 | 2020-12-29 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
CN109651358B (zh) * | 2017-10-11 | 2023-04-07 | 上海迪诺医药科技有限公司 | 4-氨基吡啶衍生物、其药物组合物、制备方法及应用 |
CN113292567A (zh) * | 2020-04-08 | 2021-08-24 | 迪斯凯威(深圳)新药发展有限公司 | 一种核苷酸衍生物及其药物组合物和用途 |
AU2022387700A1 (en) * | 2021-11-12 | 2024-05-30 | Suzhou Spring-Sea Bio-Pharmaceuticals Co., Ltd. | Ester derivatives of n4-hydroxycytidine and use thereof |
-
2022
- 2022-08-29 CN CN202211039144.9A patent/CN115960148B/zh active Active
- 2022-08-29 WO PCT/CN2022/115474 patent/WO2023025319A1/zh unknown
- 2022-08-29 CN CN202410040619.9A patent/CN117886870A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104884462A (zh) * | 2012-10-29 | 2015-09-02 | 共晶制药股份有限公司 | 用于治疗病毒感染和癌症的嘧啶核苷及其单磷酸酯前药 |
CN107427529A (zh) * | 2014-12-26 | 2017-12-01 | 埃莫里大学 | N4‑羟基胞苷和衍生物及与其相关的抗病毒用途 |
CN111372592A (zh) * | 2017-12-07 | 2020-07-03 | 埃默里大学 | N4-羟基胞苷及衍生物和与其相关的抗病毒用途 |
CN111971284A (zh) * | 2017-12-27 | 2020-11-20 | 埃默里大学 | 核苷和/或nadph氧化酶(nox)抑制剂作为髓样特异性抗病毒剂的联合模式 |
WO2021159044A1 (en) * | 2020-02-07 | 2021-08-12 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
CN111548384A (zh) * | 2020-03-29 | 2020-08-18 | 常州安蒂卫生物科技有限公司 | 用于抗新型冠状病毒治疗的被取代的n4-羟基胞苷衍生物及其前药 |
Non-Patent Citations (1)
Title |
---|
P. SURESH JAYASEKARA, MATTHEW O. BARRETT, CHRISTOPHER B. BALL, KYLE A. BROWN, EVA HAMMES, RAMACHANDRAN BALASUBRAMANIAN, T. KENDALL: "4-Alkyloxyimino Derivatives of Uridine-5′-triphosphate: Distal Modification of Potent Agonists as a Strategy for Molecular Probes of P2Y 2 , P2Y 4 , and P2Y 6 Receptors", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 57, no. 9, 8 May 2014 (2014-05-08), US , pages 3874 - 3883, XP055229056, ISSN: 0022-2623, DOI: 10.1021/jm500367e * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11963967B2 (en) | 2020-10-16 | 2024-04-23 | Gilead Sciences, Inc. | Phospholipid compounds and uses thereof |
US12030904B2 (en) | 2023-04-14 | 2024-07-09 | Gilead Sciences, Inc. | Phospholipid compounds and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
CN117886870A (zh) | 2024-04-16 |
CN115960148B (zh) | 2023-12-12 |
CN115960148A (zh) | 2023-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2023025319A1 (zh) | 一种新型的胞苷衍生物及其药物组合物和用途 | |
CA2460682C (en) | Ester compound and medical use thereof | |
US20220112177A1 (en) | Ketoamide compound and preparation method, pharmaceutical composition, and use thereof | |
CN105849100B (zh) | 流感病毒复制抑制剂 | |
JP3087763B2 (ja) | 新規な複素環式化合物およびそれを含有する医薬組成物 | |
US20140018418A1 (en) | Methods of treating or preventing h5n1 influenza | |
JPH0326183B2 (zh) | ||
WO2020107500A1 (zh) | 2-(1-酰氧正戊基)苯甲酸与碱性氨基酸或氨基胍形成的盐、其制备方法及用途 | |
DK155792B (da) | Analogifremgangsmaade til fremstilling af pyrrol-eddikesyreamider eller salte deraf | |
WO2018174442A1 (ko) | 코로나 바이러스 감염으로 인한 질환 치료용 화합물 | |
CN115135646B (zh) | 取代的多环化合物及其药物组合物和用途 | |
JP3647451B2 (ja) | ベンゾラクタム誘導体 | |
JPH02124884A (ja) | N―置換アミド誘導体 | |
WO2020098710A1 (zh) | 一种取代的双芳香基酰胺化合物及其制备方法和应用 | |
US6300368B1 (en) | Anilide derivatives and antiarrhythmic agents containing the same | |
WO2019201255A1 (zh) | 异吲哚衍生物 | |
JP6958797B2 (ja) | C型肝炎ウイルス阻害剤およびその使用 | |
CN116589518A (zh) | 一种新型的胞苷衍生物及其药物组合物和用途 | |
EP1844775A1 (en) | Therapeutic agent for herpes progenitalis | |
CN116284048B (zh) | 一种化合物及其制备方法、药物组合物和用途 | |
CN113603689B (zh) | 多环吡啶酮化合物及其药物组合物和用途 | |
WO2023226614A1 (zh) | N-(吡啶-2-基)吡啶-2-硫代酰胺或其盐在制备抗缺氧药物中的用途 | |
CN111100079B (zh) | 一类常山碱衍生物及其制备方法和应用 | |
JPH0466568A (ja) | 中枢性抗酸化剤化合物 | |
CN113583022A (zh) | 多环化合物及其药物组合物和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22860665 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |